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xi 
Inhalants are a loosely defined diverse group of volatile substances which people 
abuse. Despite widespread misuse of inhalants, there are limited preclinical methods 
available to study the reinforcement-like properties of inhalants. One procedure which has 
demonstrated substantial promise as a tool to investigate inhalant pharmacology is the 
intracranial self-stimulation (ICSS) procedure. ICSS utilizes pulses of electrical 
stimulation to the mesolimbic reward pathway to serve as a temporally defined and 
controlled operant reinforcer with a highly adjustable efficacy. The first aim of the project 
was to characterize the effects of commonly abused inhalants: including toluene, 
trichloroethane, nitrous oxide, isoflurane and R134a in ICSS.  
The second aim was to attenuate inhalant-facilitated ICSS by utilization of 
compounds which would attenuate the pharmacological actions of toluene on GABAA 
receptors. The low efficacy benzodiazepine negative modulator Ro15-4513 significantly 
attenuated the ability of toluene to facilitate ICSS without itself significantly altering 
baseline ICSS responding. Pretreatment with Ro15-4513 also attenuated methamphetamine 
ICSS even though there is no evidence of methamphetamine interacting with GABAA 
receptors. Given these unexpected results, I employed a microdialysis procedure to 
examine the effect of Ro15-4513 on methamphetamine stimulated dopamine release in the 
nucleus accumbens. Pretreatment with Ro15-4513 significantly attenuated 
methamphetamine stimulated dopamine release while having a negligible effect on 
dopamine release when administered alone. These results suggest that a modest level of 
benzodiazepine-site negative modulation can reduce the reinforcement enhancing effects 
of abused drugs regardless of their primary mechanism of action through allosteric 
xii 
modulation of GABAergic neurons within the mesolimbic pathway. Further, these results 
may have implications for expanding the examination of GABAA negative modulator 
medications beyond those trials currently being conducted with alcohol. 
Finally, the effects of chronic intermittent toluene exposure on ICSS and nesting 
behaviors were examined. Subjects were systemically exposed to air, chronic intermittent 
toluene (CIT), or escalating chronic intermittent (ECIT) toluene for 15 min at 3300 PPM 
toluene vapor per exposure. The results show that ECIT resulted in decreased overall 
responding in ICSS relative to air control and showed a tolerance-like effect to facilitatory 
effects of 3300 ppm toluene during ICSS compared to CIT group. These results indicate 
that escalating use of toluene produces reductions in its reward-like effects and may 
contribute to escalation to other drugs of abuse. 
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Background and Significance 
Inhalants Defined 
Inhalants are a pharmacologically diverse group of compounds that have been 
ubiquitously defined through the exclusivity of the inhalational route by which humans 
abuse them. In addition, inhalants are associated with their legal, therapeutic and 
commercial availability in society. Broadly defined, this loosely categorical ascription 
presents a unique challenge in defining their place amongst the various drug classes which 
are all generally grouped by pharmacological action. For example, many drugs such as 
marijuana, crack cocaine or crystal methamphetamine are highly abused via the inhalation 
route and yet are not considered to fall within the scope of the definition of an inhalant. 
Despite the lack of a clear cut, universally accepted, definition for what constitutes an 
inhalant, for most purposes the amorphous definition of an abused inhalant conforms to the 
following taken from a inhalant debate article addressing this exact issue (Balster et al, 
2009): “Abused inhalants contain volatile substances that are self-administered as gases or 
vapors to induce a psychoactive or mind-altering effect. These volatile substances are 
available in legal, relatively inexpensive and common household products, which can be 
gases, liquids, aerosols or, in some cases, solids (mothballs)” (Cheong et al, 2006; Kong 
and Schmiesing, 2005; Weintraub et al, 2000). 
Further clouding the already socially constructed definition of inhalants is what 
criteria could or should be used to group them. One approach is to group inhalants by a 
combination of their physical and chemical properties and their functional role in either 
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therapeutic or commercial settings. For example, the volatile and gas anesthetics which are 
used clinically for their anxiolytic and anesthetic properties fall into one set of categories 
while commercially viable products that contain abused solvents or gases fall into another 
(Table 0, Modified from (Howard et al, 2011). 
Table 0 
Intended Use Volatile solvents Gases 
 Anesthetics Sevoflurane, Isoflurane, Halothane Nitrous Oxide, Xenon 
Commercial 
Adhesives 
Toluene, ethyl acetate, methyl chloride — 
Vehicle fuels and 
accessories 
n-hexane, toluene, xylene Nitrous Oxide, R134a 
Cleaners Toluene, acetone, trichloroethane R134a 
Food Preparation — Nitrous Oxide 
 
A more rational and useful proposal is to group inhalants based upon their similar 
or unique pharmacological actions (Balster et al, 2009). However, the promiscuity of 
inhalants to alter the function of a large number of receptors and their receptor subtypes 
has made distinct categorization of inhalants extremely difficult. For example, the 
prototypical and arguably one of the most well studied of the commercial inhalants, 
toluene, has an incredibly diverse profile of pharmacological action, acting as a positive 
allosteric modulator, negative allosteric modulator, antagonist or non-competitive 
antagonist at the following channels: AMPA , NMDA, GABAA, Glycine, 5HT3, nAChR, 
ATP, sodium channels, voltage-gated calcium channels, potassium channels and gap 
junctions (Cruz et al, 2014). Substantial overlap between the effects of toluene and the 
gaseous anesthetic nitrous oxide exist, in that it too has effects on nAChR (Suzuki et al, 
2003; Yamakura and Harris, 2000), calcium channels (Fan et al, 2007), AMPA 
(Mennerick et al, 1998), NMDA (Jevtović-Todorović et al, 1998; Ranft et al, 2007; 
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Yamakura and Harris, 2000) and GABAA receptor (Hapfelmeier et al, 2000; Mennerick et 
al, 1998).  
 Due to research interest in enhancing the safety profile of therapeutic anesthetics, 
there is a great deal of ongoing research involved in isolating their binding site(s). 
(Borghese et al, 2006; Lecker et al, 2013; Werner et al, 2011). In mutant models of 
GABAA receptors, it has been demonstrated that point mutations of key proteins can 
dramatically reduce the overall pharmacological effectiveness of anesthetics to produce 
anesthesia (Borghese et al, 2006). 
In contrast to toluene, nitrous oxide and volatile anesthetics, we know relatively 
little regarding the neurochemical pharmacology of the many other abused inhalants that 
are volatile constituents in commercial products (e.g. trichloroethane) and almost nothing 
regarding other abused inhalants such as refrigerants (e.g. 1,1,1,2-tetrafluoroethane/ 
R134a) (Ritchie et al, 2001).  
Likewise, other inhalants that have been examined appear to also have multiple 
receptor interactions. Given the vast diversity of receptors impacted by inhalants there is 
enormous utility in quantifying the importance of specific targets to the abuse-related 
effects of inhalants. However, at this time differences across experimental conditions and 
incomplete data make synthesis of complete system wide catalogues of affected receptors 
and receptor subtypes difficult to construct. Though substantial efforts have been made 
within the last decade towards identifying the primary receptor systems that contribute to 
the abuse related effects of inhalants (Cruz et al, 2014). 
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Inhalant Abuse Epidemiology 
Initiation of use and Abuse 
 Inhalants are often reported as being some of the first abused drugs in a subject’s 
lifetime, largely due to the limited regulation and application of controlled monitoring 
systems and their widespread availability in products accessible to youth. The monitoring 
the future 2016 report estimates that over one million adolescents have abused an inhalant 
in the past year (Johnston, L. D., O’Malley, P. M., Miech, R. A., Bachman, J. G., & 
Schulenberg, 2016) and these numbers are as high as 18.8% in the developing world 
(Akoijam et al, 2013). There is also growing recognition of inhalant abuse in the armed 
forces, due in part to their low cost, ubiquitous availability and undetectable nature in 
standard drug screening tests (Lacy and Ditzler, 2007). Despite the severity of the 
consequences following inhalant use as well as their relatively high abuse rates, inhalants 
represent one of the least studied areas within the field of drug addiction research.  
Diversion and Abuse of Inhalants 
Toluene is a volatile organic solvent found in a wide range of consumer and 
industrial products including paint thinner, glues, and gasoline. Due in part to its ability to 
dissolve hydrophobic organic compounds, toluene is almost universally included as an 
emulsifying agent across a diverse array of commercial products and therefore remains one 
of the most widely accessible of the abused inhalants (Garland et al, 2009; Howard et al, 
2011). Other inhalants which continue to be abused at lesser rates, often with fatal 
consequences, include nitrous oxide, trichloroethane, R134a and isoflurane (Koehler and 
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Henninger, 2014; Meadows and Verghese, 1996; Pavlic et al, 2002; Wu et al, 2004). Some 
inhalants appear to be abused at much higher rates in certain demographics (Hout and 
Bingham, 2013; Howard et al, 2008; Wagner et al, 2012) or in developing countries 
(Praharaj et al, 2008). Abuse of other inhalants such as the solvent 1,1,1-trichloroethane 
and the refrigerant, chlorodifluromethane (R22/Freon) and 1,1,1-2-tetrafluoroethane 
(R134a) have seen decreased production and reduced use in the United States in part as a 
result of the Montreal Protocol, which has provisions to phase out and eliminate the 
harmful environmental impact of short halogenated alkyl-chain hydrocarbons (United 
Nations Environment Programme Environmental Effects Assessment Panel, 2016). 
However, R134a is still very much commercially available as a refrigerant and propellant 
in air duster canisters. Means of diversion of R134a primarily come from abuse of 
computer duster sprays and theft from air conditioning units (Caplan et al; Garland and 
Howard, 2010, 2012).  
Volatile anesthetics are also subject to abuse. For instance, the volatile anesthetic 
isoflurane has no industrial or commercial use outside of biomedical sciences or human 
and veterinary medicine and the populations who abuse it are generally found to belong to 
these communities. Information regarding abuse rates are not well established as there are 
restricted mechanisms in place to prevent significant diversion to individuals outside the 
veterinary, biomedical sciences and medical establishments. However, several cases of 
volatile anesthetic abuse resulting in death have been documented in the literature (Fry and 
Fry, 2015; Jacob et al, 1989; Kuhlman et al, 1993; Levine et al, 2007; Pavlic et al, 2002; 
Rosales et al, 2007; Spencer et al, 1976). Interestingly, with increasing use of near 
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untraceable cryptocurrency and the rise of encrypted dark net marketplaces such as ‘Silk 
Road 3.0’, diversion of restricted anesthetics is becoming increasingly accessible to 
individuals outside of the medical and scientific communities (Hout and Bingham, 2013). 
Among anesthetics, nitrous oxide also sees heavy commercial use as an anti-
microbial food propellant in addition to its therapeutic medical use as an anesthetic adjunct 
in medicine and dentistry (Balster et al, 2009; Brouette and Anton, 2001). It is primarily 
through its wide use in food and in some instances automotive services that allows it to be 
unregulated, commercially distributed and sold through head shops or major online retail 
vendors. 
Subjective Intoxicating Effects of Inhalants 
When inhaled for recreational purposes, toluene and trichloroethane produce a 
rapid onset of psychoactive effects, including excitation and euphoria, while higher 
concentrations can cause sedation, fatigue, respiratory depression, coma and death (Cruz 
and Domínguez, 2011; Diana, 2011; Elkoussi and Bakheet, 2011; Winek et al, 1997). 
Nitrous oxide produces a myriad of psychoactive effects including euphoria, fatigue, 
numbing sensations, and detachment (Collado et al, 2007). When R134a in computer 
duster or from a refrigerant is inhaled, drug effects include euphoria, dementia, fatigue, 
aggression, insomnia, slurred speech, depression, and memory deficits (Caplan et al; 
Garland and Howard, 2010, 2012). While access to volatile anesthetics is limited, 
intentional inhalation of isoflurane produces sedation, ataxia, disruption of one’s 
perception of time and decreased neuronal activation in a brain activation induced task 
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(Beckman et al, 2006; Cheeseman et al, 2012; Heinke and Schwarzbauer, 2001; Zacny et 
al, 1996). 
Medical Consequences 
Gaseous inhalants have the potential to result in asphyxiation due to hypoxia from 
their displacement of oxygen when they are continuously inhaled. The central nervous 
system depressant effects of inhalants also decrease self-awareness and motor function, 
reducing one’s ability to discontinue inhalation which can lead to death from sustained 
hypoxic oxygen concentrations. 
Exposures to inhalants have been linked to a number of severe medical conditions 
including arrhythmias (King et al, 1985), myeloneuropathies (Pema et al, 1998; Tatum et 
al, 2010), immune dysfunction (Fujimaki et al, 2011), as well as abnormal developmental 
conditions such as fetal solvent syndrome (Bowen and Hannigan, 2006; Bowen, 2011; 
Hannigan and Bowen, 2010; Jones and Balster, 1998). Inhalant exposure can also result in 
damage to key enzymes necessary for the production of myelin (Flippo and Holder, 1993; 
Wu et al, 2007) and neurocognitive impairment (Beckley and Woodward, 2013). Chronic 
nitrous oxide abuse has been associated with vitamin B12 deficiency and 
myeloneuropathies leading to Pseudo-Guillain-Barre syndrome (Lin et al, 2011; Tatum et 
al, 2010).  
R134a’s significant ability to absorb heat across phase changes makes it an ideal 
refrigerant. Unfortunately, when used as an abused inhalant from air dust canisters the 
compressed R134a liquid is discharged directly from the canister producing a rapid 
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decrease in temperature as it moves from a liquid to a gas, resulting in the possibility of 
very serious tissue damage. Angioedema and frostbite of respiratory tissue has been 
observed from repeated inhalation and rapid discharge of air dust canisters (Koehler and 
Henninger, 2014; Winston et al, 2015). Several frostbite cases have been recorded in the 
literature as well when the users have direct contact of their skin on an opened valve that 
discharges compressed nitrous oxide as the gas can reach temperatures as low as -55° C 
(Hwang et al, 1996; Svartling et al, 1996). Chronic toluene exposure has been shown to 
produce neurotoxicity as well as detrimental effects on reproductive, pulmonary, renal, 
cardiovascular, and hepatic organ systems (Bowen and Hannigan, 2006; Gupta et al, 2011; 
Hannigan and Bowen, 2010; Hoet and Lison, 2008; Yücel et al, 2008). 
Inhalant Pharmacology  
Physical Properties 
Inhalants are characterized by their low-boiling point, high vapor pressure and high 
lipophilicity. The lipophilic properties of inhalants facilitate their transfer across the blood-
brain barrier where they can exert their influence on protein receptor targets. The high 
lipophilicity of inhalants engenders their affinity to bind within pockets of transmembrane 
domain regions of ion channels. In general, most ion channels are highly susceptible to 
being influenced by inhalants/anesthetics and accumulating evidence suggests it is through 
interaction in transmembrane domain regions that inhalants are able to exert their 
neurochemical effects (Brosnan and Pham, 2014; Li et al, 2010; Mihic et al, 1997; Werner 
et al, 2011). Inhalants vary in their ability to induce conformational changes across either 
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specific or combinations of specific ion channel receptors and their subtypes (Brosnan and 
Pham, 2014). Currently, there is strong evidence that many of the neurochemical effects of 
inhalants are produced through specific receptors or through modulation of combinations 
of specific receptors with specific importance placed upon gamma amino butyric acid 
subtype A (GABAA) and N-methyl-D-aspartate receptors (NMDA) (Bale et al, 2005; 
Beckstead et al, 2000; Belelli et al, 1999; Jurd et al, 2003; Lecker et al, 2013; Mennerick 
et al, 1998; Zhou et al, 2012). In addition numerous behavioral experiments in vivo have 
implicated the GABAA receptor system as being one of the more important systems that 
contribute to their subjective effects (Shelton and Nicholson, 2010, 2013). 
 Toluene 
Toluene produces reward-like effects in multiple behavioral assays including 
conditioned place preference (Gerasimov et al, 2003; Lee et al, 2006), self-administration 
(Blokhina et al, 2004), and intracranial self-stimulation (Chan et al, 2012; Tracy et al, 
2014, 2015; Yavich and Zvartau, 1994). Within the drug discrimination procedure, 
toluene’s subjective effects can be studied across a wide variety of parameters. Depending 
on the specific experimental conditions and whether toluene is used as either the training 
drug or is the drug of substitution for another training compound, toluene has been shown 
to share discriminative stimulus properties with other inhalants as well as ethanol, 
dopaminergic, GABAergic, and NMDAergic drugs of abuse (Bowen, 2006; Bowen et al, 
1999; Rees et al, 1987; Shelton and Nicholson, 2013). Neuropharmacologically, toluene 
has been shown to be a positive allosteric modulator of glycine receptors and to 
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allosterically enhance the chloride current amplitude and the frequency of inhibitory post-
synaptic currents through GABAA receptors (Beckstead et al, 2000; MacIver, 2009). 
Significant focus has also been given to the non-competitive antagonist effects of toluene 
on NMDA receptors (Bale et al, 2005, 2007; Cruz et al, 1998, 2000). Additional ion 
channels have been shown to be affected by toluene exposure: 5-HT3 (Lopreato et al, 
2003), nAChR (Bale et al, 2002), and purinergic (Woodward et al, 2004). When injected 
locally into the VTA, there is evidence that toluene either directly or indirectly activates 
dopaminergic projecting neurons that project to the nucleus accumbens(Apawu et al, 2015; 
Riegel et al, 2007). However, the toluene binding site of the receptor protein-target that 
may mediate this effect in the mesolimbic pathway has not been determined. In addition, 
there is no neuropharmacological evidence of volatile organic solvents or compounds 
directly activating metabotropic receptors in the absence of ionotropic receptors that are 
co-expressed in native cell cultures. 
Nitrous Oxide 
Quantifying the reward-related effects of nitrous oxide in animal models has been 
difficult due in part to complications of working with a purely gaseous substance. 
However, there is one example of nitrous oxide self-administration with squirrel monkeys. 
Given the option to respond for access to 15, 30 and 60 seconds of nitrous oxide, monkeys 
will self-administer the gas well above air rates (Wood et al, 1977). Conversely in rodents, 
nitrous oxide was poorly self-administered and produced conditioned place aversion 
(Ramsay et al, 2003). In drug discrimination, when exposure to 60% nitrous oxide is 
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trained as the discriminative stimulus, exposure to toluene shows near-full substitution 
with lower rates of partial substitution for other abused solvents and anesthetics including 
ethanol, isoflurane, trichloroethane and methoxyflurane, which would be consistent with 
the diverse and overlapping pharmacological actions of inhalants (Richardson and Shelton, 
2014). Interestingly, the NMDA antagonist (+)-MK-801 significantly reduced the nitrous 
oxide concentration necessary to fully substitute for a training concentration of 60% 
nitrous oxide, suggesting that NMDA antagonism plays a substantial role in nitrous oxide’s 
discriminative stimulus effects (Richardson and Shelton, 2015). In contrast, GABAergic 
specific compounds did not produce significant levels of substitution for nitrous oxide nor 
did they enhance the ability of lower concentrations of nitrous oxide to substitute for the 
training concentration of itself.  
In in vitro expression systems, nitrous oxide exposure non-competitively inhibits 
NMDA receptors (Jevtović-Todorović et al, 1998; Mennerick et al, 1998). However, 
positive modulation of GABAA receptors is small compared to other volatile anesthetics 
such as isoflurane (Yamakura and Harris, 2000). Concentrations necessary to induce larger 
changes in GABAA receptor function require non-physiologically attainable concentrations 
of nitrous oxide: (100% or the maximum partial pressure concentration attainable by 
Henry’s Law at 1 atmosphere: 29.2 mM) (Hapfelmeier et al, 2000). Lastly, nitrous oxide 
has also been shown to inhibit nicotinic acetylcholine receptors (Suzuki et al, 2003; 
Yamakura and Harris, 2000), calcium channels (Fan et al, 2007), and AMPA receptors 
(Mennerick et al, 1998).  
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1,1,1-Trichloroethane (TCE) 
TCE produces reward-like effects in self-administration (Blokhina et al, 2004) and 
shares some discriminative stimulus properties with GABAergic drugs of abuse as 
evidenced by pentobarbital, midazolam and diazepam producing high partial substitution 
in mice trained to discriminate TCE (Shelton and Nicholson, 2012). However, for mice 
trained to discriminate the NMDA antagonist dizocilpine, TCE failed to produce any 
substitution (Shelton and Balster, 2004). TCE has been shown to produce positive 
allosteric modulatory effects on both GABAA and glycine receptors (Beckstead et al, 2000; 
MacIver, 2009). Like toluene, TCE has non-competitive antagonist effects on the NR1/2B 
subtype of NMDA receptors (Bale et al, 2005, 2007; Cruz et al, 1998, 2000) as well as 
enhancing the function of 5-HT3 (Lopreato et al, 2003). 
Isoflurane 
While there has been relatively little neurobehavioral research characterizing the 
abuse related effects of isoflurane, its discriminative stimulus properties have been 
characterized in mice. In mice trained to discriminate 6,000 ppm isoflurane from air, 
pentobarbital, midazolam and zolpidem produced high levels of substitution indicating a 
substantial GABAergic component of isoflurane’s discriminative stimulus (Shelton and 
Nicholson, 2010). In substitution tests, the abused inhalants (TCE, toluene) and volatile 
anesthetics (enflurane, halothane) all produced full substitution for isoflurane, however 
nitrous oxide and the NMDA antagonist L-701,324 did not substitute at all. 
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Due in part to isoflurane’s continued use as an anesthetic agent in clinical practices 
and evidence of a more substantial contribution of the GABAA complex to its mechanism 
of action (Yamakura and Harris, 2000), there is considerable interest in isolating the 
binding pockets within the hetereopentameric GABAA receptor that contribute to its 
effects. Point mutations in recombinant systems have isolated transmembrane domains 
within the β2/3 subunit that confer reduced sensitivity to isoflurane induced potentiation of 
GABAA receptors (Rudolph and Möhler, 2004). Dual point mutations within the α1 subunit 
(Borghese et al, 2006) and α2 subunit (Sonner et al, 2007) at transmembrane domain 2 
(S270H, L277A) render the GABAA receptor substantially less sensitive to isoflurane; 
However, compared to wild-type mice, mutants showed a lower sensitivity and faster rate 
of termination of GABAergic signaling. In addition, knock-in mice homozygous for the α1 
mutations showed significantly higher rates of baseline locomotor activity during the light 
and dark cycles, therefore the authors were unable to exclude the possibility that the 
mutation affected normal receptor function rather than simply blocking the allosteric site 
binding pocket. Knock-in mice homozygous for the α2 mutation showed a small but 
significant reduction in the loss of righting reflex, suggesting a contribution from this 
subtype in isoflurane’s motor impairing effects. More recently, isoflurane exposure has 
been found to competitively displace a photolabeled azietomidate (etomidate analog) 
which binds within the transmembrane domain of the β subunit (Li et al, 2010). 
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1,1,1,2-tetrafluoroethane (R134a) 
To date, no electrophysiological experiments have been conducted to determine the 
functional consequences of R134a exposure at ligand gated ion channels. A search of the 
PubMed database using the search terms “134a abuse, HFC 134a, R134a, computer duster 
abuse, or R134a abuse” revealed only one basic sciences study that examined abuse-like 
behavioral effects of concentrations of inhaled R134a on a series of neurobehavioral 
measures in rats (Ritchie et al, 2001). In this study, Wistar rats were exposed to HFC 134a 
before and during testing for neurobehavioral complications in a rotawheel apparatus, 
operant responding for a food reinforcer, seizure induction, and for sedative and anesthetic 
effects. At abuse-like concentrations of 40,000 to 470,000 ppm, rats showed significantly 
more errors in performance on an operant task for food maintained responding and gross 
motor impairment on the rotawheel apparatus. When oxygen was not coadministered with 
R134a, subjects exhibited generalized tonic-clonic seizures (Ritchie et al, 2001). 
 
Intracranial Self-stimulation: Procedure, Strategies, Neurocircuitry, Utility for 
Inhalant Studies, and Aspects of Test Validity 
Strategies for Understanding the Reinforcing Properties of Inhalants 
Despite being inexpensive, readily available and having abuse liability, the 
mechanism or mechanisms underlying the reinforcing effects of inhalants are poorly 
understood (Bowen and McDonald, 2009; Howard et al, 2011). One reason this may be the 
case is the lack of validated in vivo procedures for examining abuse-related effects of 
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inhaled substances. While the intravenous self-administration procedure is the most widely 
utilized paradigm to assess drug reinforcement and mechanisms of action, it is difficult to 
conduct self-administration studies with contingent delivery of inhaled vapors or gases. To 
date only one study has demonstrated intravenous self-administration of an inhalant and 
that experiment used a novel between-subject single day acquisition procedure in mice 
(Blokhina et al, 2004).  
Intracranial Self-stimulation Procedure 
The phenomenon of direct electrical stimulation of the brain producing robust 
reward-like behavioral effects was serendipitously first discovered in the 1950s with the 
seminal work of Olds and Milner (Olds and Milner, 1954). The discovery as retold by 
Milner, recounts that they (Olds and Milner) were interested in studying the brainstem 
reticular formation via direct electrical stimulation with implanted electrodes (Milner, 
1991). In general, stimulation of this region produces aversive effects with locations that 
are associated with the stimulation being actively avoided. Olds, just having learned the 
surgical implantation procedure observed that one subject, rather than exhibiting the 
typical avoidance was showing robust appetitive behaviors and would spend more time in 
the location where the electrical stimulation was delivered. Further investigation revealed 
the electrode was incorrectly implanted, and that rather than being in the brainstem 
reticular formation the stimulating portion of the electrode was found to be in the septal 
region. Direct electrical stimulation of the septal region was subsequently found to 
function as a robust reinforcer that could be utilized to train new behaviors such as operant 
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lever pressing (Milner, 1991). In subsequent studies, electrical stimulation of many brain 
regions was found to support ICSS behavior including the prefrontal cortex, septal, nucleus 
accumbens, ventral tegmental area and the medial forebrain bundle (MFB), with the MFB 
supporting the highest rates of responding (Negus and Miller, 2014). 
A novel feature of the brain stimulation reward phenomenon is that it is unlike 
natural reinforcers such as food or sex, there are no negative-feedback mechanisms in 
place to satiate the motivated behavior. Indeed, subjects are observed to tirelessly engage 
in responding for the brief electrical pulses and even endure aversive stimuli in order to 
maintain continued delivery of the highly efficacious reinforcer (Milner, 1991). In 
addition, the electrical and temporal parameters that determine the reinforcing magnitude 
of brain reward stimulation can be altered instantaneously to produce robust patterns of 
responding across a relatively small interval of time. Certain methodologies have been 
developed which take advantage of the strength of the behavior such as the threshold and 
rate-frequency procedures.  
The rate-frequency procedure of ICSS (among others) has been utilized as a tool to 
study a wide spectrum of behavioral and neuropharmacological phenomena. These 
include: pharmacological mechanisms (Kelley and Hodge, 2003; Markou and Koob, 1992; 
Reynolds et al, 2012; Schaefer and Michael, 1989), abuse-liability assessment (Corbett, 
1989; Schaefer and Michael, 1987; Yavich and Zvartau, 1994), state-dependent effects 
such as depression (Slattery et al, 2007), withdrawal (Lin et al, 1999; Manbeck et al, 2014; 
Markou and Koob, 1991; Schulteis et al, 1995), anxiety and post-traumatic stress disorder 
(Reznikov et al, 2016) or pain-depressed behavior (Negus et al, 2010). 
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Neurocircuitry Involved in ICSS 
 Critical mesolimbic reward circuits are involved in maintaining ICSS behavior. 
Multiple electrophysiological collision studies indicate there is strong evidence that 
ascending unmyelinated dopaminergic neurons in the ventral tegmental area projecting to 
the nucleus accumbens are the critical last stage pathway in the neurocircuitry of MFB 
stimulation in ICSS (Yavich and Tiihonen, 2000). Activation of VTA dopaminergic 
projection neurons by direct electrical stimulation of the MFB involves a multiple stage 
process with intermediaries that are not entirely understood, but some evidence suggests 
glutamatergic and cholinergic processes are involved in MFB stimulation (Kempadoo et 
al, 2013; Singh et al, 1997). Electrophysiological studies in which collisions between 
paired pulses between two electrodes that stimulate regions at varying times from the MFB 
and the VTA suggest that descending myelinated axons are the first stage component to 
activating VTA dopaminergic neurons (Bielajew and Shizgal, 1980, 1986). More recently, 
optogenetic studies have implicated descending glutamatergic fibers and neurotensin 
receptors within the ventral tegmental area as contributing to the first stage of electrical 
brain stimulation in the MFB at the level of the lateral hypothalamus, though multiple 
receptor systems may contribute to maintaining ICSS behavior (Kempadoo et al, 2013). 
Adapting ICSS to Study Inhaled Vapors and Gases 
Most classes of abused drugs facilitate ICSS-reinforced behavior (Fish et al, 2010; 
O’Neill and Todtenkopf, 2010; Straub et al, 2010). Likewise, the intracranial self-
stimulation (ICSS) procedure has been shown to be adaptable to examining the reward-
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related effects of inhalants. Two studies in rats conducted a number of years ago 
demonstrated that, similar to other drugs of abuse, toluene vapor facilitates ICSS 
responding (Bespalov et al, 2003; Yavich and Zvartau, 1994). In both studies toluene 
vapor exposure significantly enhanced responding for lower stimulation intensities as well 
as decreased self-stimulation thresholds. 
The development of ICSS procedures to examine the reward-related effects of 
inhalants in mice is of particular interest given the powerful genetic tools available only in 
mice. Mimicking the route a drug is abused in humans has traditionally been thought to be 
of limited importance in preclinical studies, and it has been shown that intraperitoneal 
injected toluene reduces ICSS thresholds in mice in a discrete-trial current-threshold 
procedure (Chan et al, 2012). However, a recent c-Fos expression study in rats 
demonstrated administration route-dependent differences in neuronal activation produced 
by toluene (Perit et al, 2012). Among the important neuronal systems differentially 
affected by administration route were areas associated with reward and motor control, with 
inhaled toluene producing significant increases in c-Fos expression in the nucleus-
accumbens core and caudate-putamen relative to the findings of a previous study using 
injected toluene (Lo and Chen, 2005). While c-Fos is only a proxy for neuronal activation, 
the significance of route-dependent increases in neuronal activation coupled with the fact 
that toluene is abused exclusively by inhalation supports studying the reward altering 
effects of liquid volatile inhalants through their abused inhalation route. Further, the use of 
inhalation exposure is the only route through which abused gaseous compounds such as 
nitrous oxide, R134a, R12 or xenon can be evaluated. An additional component that may 
32 
differentiate the abuse-related effects of inhalants given by the injection versus inhalation 
is the rapid kinetics of inhalant uptake and the immediacy of their pharmacological effects 
that occur following inhalation. The rate of onset of the pharmacological effects for other 
drugs of abuse, in particular inhalation of smoked crack-cocaine versus insufflated cocaine 
hydrochloride, strongly contributes to the abuse-liability of the substance (Hatsukami and 
Fischman, 1996). 
Aspects of Test Validity in ICSS 
The gold standard in abuse-liability assessment in non-human subjects has been the 
self-administration procedure given the obvious similarity to human drug taking behavior. 
In this procedure, animals are placed into an apparatus in which drug can be contingently 
delivered based upon completion of an operant schedule.  
A number of issues arise when attempting to utilize self-administration with 
inhalants. One is the difficulty with establishing a controlled dose of an inhalant over a 
short time period. Another is that contingent vapor delivery may have transitory aversive 
effects that might be very tightly associated with the operant behavior that causes its 
delivery. For human subjects this has not been an issue and there are numerous examples 
in the literature where individuals will endure mild to moderate discomfort for the reward-
like effects that occur from inhaling compounds that cause brief aversive effects (Hwang et 
al, 1996; Koehler and Henninger, 2014; Praharaj et al, 2008; Svartling et al, 1996). These 
aversive effects such as extreme cold from a compressed inhalant undergoing a phase 
change and vaporizing or the burning sensation of a solvent on sensitive epithelial tissue 
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can then enter into complex associations where they can come to function as a conditioned 
reinforcer. However, for most model organisms these effects serve as a strong deterrent for 
drug consumption and can make an effective design for self-administration very difficult to 
establish reliably (for an example of this difficulty, see Ramsay et al, 2003). Yet, there is a 
limited set of examples with higher order organisms such as squirrel monkeys where this 
has been successfully implemented (Wood et al, 1977).  
At the expense of face validity, which may itself have limited value in preclinical 
animal models, a number of difficulties associated with self-administration of inhalants can 
be sidestepped completely in ICSS. A very useful aspect which significantly enhances the 
utility of ICSS for investigating the effects of inhaled vapors and gases are that their 
reward-like effects can be examined following non-contingent inhalant delivery. Thus any 
brief aversive effects can be disentangled from processes that determine reward-like 
effects. When comparing self-administration to ICSS, ICSS shows considerable 
convergent and predictive validity with the results of self-administration (SA) studies 
across many drug classes and types (for examples see table 1). 
Table 1 
Drug SA ICSS 
Amphetamine  
 
(Alderson et al, 2004) (G J Schaefer and Michael, 1988; Todtenkopf et al, 2009) 
Cocaine  (Larson et al, 2010) (Straub et al, 2010) 
Toluene  (Blokhina et al, 2004) (Bespalov et al, 2003; Tracy et al, 2014; Yavich and Zvartau, 1994) 
Diazepam  (Griffiths and Johnson, 2005) (Sagara et al, 2008; Straub et al, 2010) 
Ethanol  (June et al, 1994) (Fish et al, 2010, 2012; Schaefer and Michael, 1987) 
Morphine  (Gaiardi et al, 1985) (Altarifi and Negus, 2011; O’Neill and Todtenkopf, 2010) 
MK-801  (Beardsley et al, 1990) (Hillhouse et al, 2014) 
Table 1: Compounds which show reward-like effects in both self-administration (SA) and 
intracranial self-stimulation (ICSS). 
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Experimental Aims 
Aim 1: The first major goal of the project was to determine if the rate-frequency 
variant of the intracranial self-stimulation procedure in C57BL6/J mice would be 
sensitive to reinforcement-enhancing effects of R134a, isoflurane, toluene, 1,1,1-
trichloroethane, (TCE), and nitrous oxide.  
Adult male C57BL/6J mice with bipolar ICSS electrodes chronically implanted 
into their medial forebrain bundle were trained to respond on a fixed-ratio schedule for 
stimulation. Once responding stabilized, the reward-altering effects of inhalants were 
examined systematically by comparing the ICSS frequency-response curves during air and 
inhalant exposure. Multiple concentrations of each compound were examined and order 
effects were minimized by using combinations of naïve and previous drug exposed animals 
(Carlezon and Chartoff, 2007). Inhalants which show reinforcement-enhancing effects in 
the rate-frequency procedure were also examined using a chained progressive-ratio (PR) 
schedule, a procedure whereby an exponentially growing number of responses are required 
for successive completions. This procedure involves generating a baseline level of 
responding under the chained PR schedule and then comparing baseline responding to 
responding during acute inhalant exposure. Cocaine and diazepam were utilized as positive 
controls as they have both been shown to facilitated ICSS (Fish et al, 2010; Straub et al, 
2010). 
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Aim 2: Determine the role of GABAA receptors in inhalant-facilitated ICSS 
Previous in vitro literature has shown that inhalants alter function of a diverse group 
of neurotransmitter receptors including the GABAA and NMDA receptors (Bale et al, 
2007; Beckstead et al, 2000; MacIver, 2009). Gamma-aminobutyric acid A (GABAA) 
neurons comprise ~30-35% of all neurons within the VTA and 90-95% of those in the NAc 
and GABAergic receptors are one of the major inhibitory contributors involved in 
modulating the mesolimbic system (Nieh et al, 2013; Taylor et al, 2014). Optogenetic 
studies have highlighted the critical role that GABAergic neurons play in modulating 
abuse-related phenomena. For example, optogenetic activation of GABAergic neurons in 
the VTA, of which a very large population function as inhibitory interneurons, produces 
conditioned place aversion as well as disrupts consumption of a sweetened drink reinforcer 
(Tan et al, 2012; van Zessen et al, 2012). Activation of GABAergic interneurons promotes 
release of GABA onto innervated targets producing an inhibitory effect. Similarly, 
pharmacological modulation of GABAA receptors has an array of effects in models of 
abuse-related behaviors such as self-administration, conditioned place preference and 
intracranial self-stimulation (ICSS) (Bossert and Franklin, 2003; Rowlett and Lelas, 2007; 
Di Scala et al, 1992). Of these behavioral endpoints, ICSS may be a particularly useful 
assay as it permits the study of drug effects on direct electrical stimulation of critical 
elements in brain reward pathways (for an extensive review of this procedure see: Negus 
and Miller, 2014).  
Most classes of abused drugs, including those acting as positive allosteric modulators 
at GABAA receptors, enhance the reinforcing effects of ICSS (Steffensen et al, 2001; 
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Straub et al, 2010). While drugs such as benzodiazepines and barbiturates positively 
modulate GABAA receptors it is also possible to negatively modulate GABAA receptors 
pharmacologically. High efficacy benzodiazepine (BDZ)-site negative modulators such as 
the beta-carboline DMCM can produce pronounced behavioral effects including 
convulsions. Lower efficacy negative modulators, in particular Ro15-4513, are capable of 
producing pro-seizure effects (Miczek and Weerts, 1987). However, Ro15-4513 can 
reduce the behavioral effects of GABAA positive allosteric modulators such as 
pentobarbital, ethanol and volatile anesthetics (Miller et al, 1989; Schaefer and Michael, 
1989; Shelton and Grant, 2001) at doses which do not promote seizure activity (Bishop and 
Laverty, 1989; Moody and Skolnick, 1988; Stinchcomb et al, 1989).  
With few notable exceptions (Dixon et al, 2010), the general focus on the utility of 
negative GABAA modulators has been on reversing the behavioral effects of ethanol. For 
instance, Ro15-4513 reduces ethanol self-administration in both rodents (McBride et al, 
1988) and primates (Shelton and Grant, 2001). Although use of Ro15-4513 as a therapeutic 
has been largely discounted, a related compound, Ro16-0154 (iomazenil) has entered 
clinical trials as a potential alcohol intoxication reversal agent (D’Souza, 2015). Given the 
key role of GABAA receptors in modulating the mesolimbic dopamine system and 
toluene’s substantial pharmacological effects upon it, the BDZ-site negative modulators 
may produce profound reductions in the abuse-related behavioral effects of other drugs that 
affect the GABAA receptor but do not act directly at the BDZ site.  
 The goal of the second aim was to investigate the role of the GABAA receptor 
system in inhalant-facilitated ICSS utilizing drugs that either block or negatively modulate 
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the benzodiazepine-site on the GABAA receptor. For these studies I utilized the 
benzodiazepine-site negative modulator RO15-4513 and the benzodiazepine-site 
antagonist flumazenil. My hypothesis was that benzodiazepine-site negative GABAergic 
modulation but not benzodiazepine-site blockade would attenuate the ICSS-facilitating 
effects of toluene. In addition to examining toluene I also assessed the ability of 
GABAergic modulators to attenuate the effects of ICSS facilitation produced by the 
dopamine releaser d-methamphetamine which served as a negative control and the GABAA 
BDZ-site positive modulator diazepam which served as a positive control. To control for 
non-specific effects, I also examined the effects of RO15-4513 and flumazenil on ICSS 
when given alone. In addition to the behavioral tests I employed a microdialysis procedure 
to determine if Ro15-4513 would attenuate dopamine release in the NAc evoked by d-
methamphetamine, a defining neurochemical characteristic of many drugs of abuse. 
 
Aim 3: Determine chronic exposure effects of inhalants on ICSS and nesting 
Withdrawal following repeated drug exposure and the state of the adaptations that 
occur in the brain’s reward system following chronic drug use are one component that is 
critical to understanding drug addiction phenomena, especially the high compulsory 
relapse rate to drug seeking and continued use despite adverse consequences. Despite the 
importance of characterizing this phenomenon at the behavioral level, a major gap in the 
inhalant literature that currently exists is how the effects of chronic inhalant abuse may 
affect generalized reward processes. One possible reason for a gap in the literature may be 
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the absence of an established procedure that examines the reinforcing efficacy of a 
reinforcer across a broad range of discreetly defined and set intensities.  
The absence of such a procedure has contributed to experiments that utilize 
behavioral assays that measure more indirect and tertiary effects of repeated chronic use of 
toluene such as how it may impact performance in behavioral assays from other drugs of 
abuse. For example, some studies have focused on how toluene exposure can produce 
locomotor sensitization effects (Bowen and Balster, 1998; Bowen et al, 2007); how 
repeated toluene exposure may affect the locomotor sensitization effects of other drugs of 
abuse such as amphetamine, MK-801, or diazepam (Duncan et al, 2014; Wiley et al, 
2003); or how toluene may impact instrumental learning-type phenomenona such as 
spatial-learning (Dick et al, 2014). 
A much subtler aspect which has been neglected in the literature is how repeated 
chronic exposure to toluene may produce cumulative effects on the mesolimbic reward 
system. For this purpose, ICSS has served as a tool for examining the cumulative 
production of anhedonic-like effects following repeated chronic intermittent exposure to 
drugs of abuse as well how cessation of continued drug exposure may manifest itself. For 
example, it is well established that acute exposure to cocaine will enhance the reinforcing 
efficacy of brain stimulation as measured by a lowering of the threshold necessary to 
maintain responding for brain stimulation. However, if cocaine is administered 
continuously through an infusion pump and is subsequently spontaneously removed, the 
threshold to maintain responding for brain stimulation will significantly increase to levels 
which are larger than that of a comparable saline control group, which would be indicative 
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of a withdrawal effect (Stoker and Markou, 2011). Anhedonic-like withdrawal effects 
following repeated chronic exposure to drugs of abuse in ICSS procedure have been 
observed across a number of different drug classes including ethanol (Schulteis et al, 
1995), morphine (Holtz et al, 2015), nicotine (Muelken et al, 2015), amphetamine (Lin et 
al, 1999), phencyclidine (Spielewoy and Markou, 2003), and in at least one case THC 
(Gardner and Vorel, 1998). 
Given the importance of understanding how repeated chronic exposure effects of 
inhalants impacts brain reward processes and the absence of behavioral studies that attempt 
to assess this at the behavioral level, my third aim examines chronic intermittent exposure 
effects on mouse behaviors in ICSS. Using the ICSS procedure to explore generalized 
effects on brain-reward systems in vivo across multiple parameters as a result of chronic 
toluene exposure had many possible avenues to explore. However, I also wanted to explore 
behaviors in the mouse that was more innate and non-operant. To this end, I also examined 
nesting behavior. Nesting is an innate behavior engaged in by mice in which they scavenge 
for materials to construct a nest. An aversive state such as pain has been observed to 
decrease the rate at which mice will gather materials to construct a nest, and this can be 
quantified by a procedure that has been developed by the Negus group (Negus et al, 2015). 
In this procedure nesting material is divided into six equal sized segments and placed along 
equal distances apart along the edge of the subject’s home cage and the time to gather all 
these nesting materials into one place is then quantified on a logarithmic time scale. 
Subjects which have an induced injury are shown to decrease the rate at which they 
complete the task and this can be reversed with analgesics such as ketoprofen (Negus et al, 
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2015). While a withdrawal state has not been specifically examined in this procedure, it is 
a reasonable conjecture that this procedure would be sensitive to aversive states other than 
pain, such as withdrawal from chronic toluene exposure.  
I have four main hypotheses to explore in this aim. My first hypothesis is that 
escalating the number of repeated chronic intermittent exposures to toluene will produce a 
cumulative decrease in overall responding for brain stimulation while in a drug free state. 
My second hypothesis is that gradually escalating the number of exposures to toluene will 
produce tolerance to the acute exposure effects in ICSS. My third hypothesis is that there 
would be a gradual decrement in the amount of brain stimulation that would be earned in a 
drug free state when subjects were exposed to an escalating chronic intermittent toluene 
exposure schedule. My fourth hypothesis is that repeated chronic intermittent exposure to 
toluene will produce gradual deficits in behaviors other than ICSS as measured in the 
nesting procedure. 
To address the first, second and third hypotheses, I chronically exposed groups of 
C57BL/6J mice to either air or different repeated chronic intermittent exposure schedules 
of 3300 ppm toluene. The air control group was only exposed to air within the ICSS test 
sessions. The repeated chronic intermittent exposure group was exposed to 3300 ppm 
toluene every 72 hours within the test ICSS sessions. The chronic escalating exposure 
group was exposed every 72 hours to 3300 ppm toluene in the ICSS test session and in 
addition was exposed to 3300 ppm toluene on an escalating exposure schedule outside of 
the chambers. These three experimental groups will address these hypotheses by 
examining how chronic intermittent toluene exposure affects the reinforcing efficacy of 
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direct electrical stimulation of the mesolimbic reward pathway; by characterizing the 
facilitation of ICSS by toluene exposure and whether repeated exposures produce 
tolerance, sensitization, or produce no effect when comparing groups that are either 
repeatedly exposed to toluene on an escalating or fixed (72 hour separation) chronic 
intermittent paradigm. It will also examine whether repeated chronic intermittent exposure 
can produce withdrawal effects in ICSS following cessation of chronic toluene exposure. 
To address the fourth hypothesis, the air control and escalating chronic intermittent 
exposure group schedules from the ICSS experiments were replicated using the nesting 
procedure. 
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Aim 1: Acute Exposure Effects of Inhalants in ICSS 
Materials and Methods 
Subjects 
 A total of 37 adult C57BL/6J mice were used (Jackson Laboratory, Bar Harbor, 
Maine). Mice were individually housed under a 12h light/dark cycle (lights on a 0600). 
Mice were tested M-F between 0800 and 1800. Chow (Harlan, Madison, WI) and water 
were available ad libitum except during experimental sessions. All procedures were 
approved by the Institutional Animal Care and Use Committee of Virginia Commonwealth 
University and were in accordance with the NIH “Guide for the Care and Use of 
Laboratory Animals: Eighth edition” (National Research Council, 2011). 
Compounds. 
 HPLC grade toluene, isoflurane and trichloroethane (TCE) were purchased from 
Fisher Scientific. R134a was purchased from an office supply company in pressurized 
canisters sold as commercial air duster. Cocaine hydrochloride was obtained from the 
National Institute on Drug Abuse drug supply program and prepared in 0.9% sterile saline. 
Diazepam was obtained in an injectable commercial formulation and diluted in 0.9% 
sterile saline. Medical grade nitrous oxide and oxygen cylinders were purchased from 
National Welders (Richmond, VA). 
Surgical Procedure 
Mice were anesthetized with isoflurane vapor and implanted with 6 mm bipolar 
electrodes (Plastics One, Roanoke, Virginia) into the right medial forebrain bundle within 
the lateral hypothalamus (Paxinos and Franklin, 2001). Coordinates relative to Bregma 
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were: -1.5 anterior-posterior, 1.0 medial-lateral, and -5.0 dorsal-ventral. Three stainless 
steel screws were affixed in holes in the skull to serve as anchors for a dental acrylic 
headpiece. Mice were treated daily for 3 days post-surgery with 0.5 mg/kg of the analgesic 
carprofen. Mice were allowed six days to recover prior to beginning ICSS training 
sessions. 
Dynamic Exposure System and Testing Apparatus 
The inhalant exposure ICSS system consisted of four 20 liter acrylic cubicles each 
of which contained a two-lever operant conditioning chamber (Med-Associates, St. 
Albans, VT). A bipolar lead tether connection (Plastics One, Roanoke, VA) and mercury 
commutator (Mercotac 205L, Carlsbad CA) was suspended above the operant conditioning 
chamber by a counterbalanced arm. Toluene and TCE vapor were produced using a 
dynamic vapor generator composed of a filtered, pressure regulated air supply routed via 
tubing to two mass flow proportional valves controlled by a Matheson 8284 dynamic gas 
mixer (Matheson, Albuquerque, NM). The air output from one valve passed through a 
fritted glass bubbler submerged below the liquid inhalant, generating an inhalant-laden air 
stream. The inhalant-laden air was mixed with metered fresh air from the second mass 
control valve permitting a broad range of highly reproducible inhalant concentrations to be 
generated. The blended vapor stream was routed through the upper rear wall of the operant 
conditioning chambers via Tygon tubing. The effluent mixture was vented from the bottom 
rear wall of the exposure chamber through a Miran 1A single wavelength infrared 
spectrophotometer coupled to a computerized chart recorder (DATAQ, Akron, OH), 
providing real time inhalant concentration measurement relative to a previously generated 
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standard curve. Inhalant vapor concentrations within each ICSS chamber were also 
quantified by headspace gas chromatography to determine exact concentrations. To deliver 
nitrous oxide, the system was similar except the inhalant and mix gas sources were 
provided by compressed cylinders. Isoflurane was delivered via a commercially available 
anesthesia machine that had been previously calibrated. R134a was delivered by routing 
multiple computer duster cans through piping to a single source pressure regulator and then 
to a Matheson rotameter. ICSS stimulation and operant schedule control was provided by 
commercially-available components (Med-Associates, St. Albans, VT). A summary 
schematic of the operant conditioning chamber housed within the gas exposure system 
with the accompanying effluent mixture piping and delivery is shown in figure 1a.  
Rate Frequency ICSS Procedure 
After surgical recovery mice were trained to respond in daily 1 hr. sessions for 
brain stimulation under a fixed ratio 1 (FR1) schedule of reinforcement. Each active lever-
press resulted in electrical stimulation consisting of a 500 ms, 158 Hz pulse train. Current 
amplitude for each subject was adjusted within a range of 50 to 300 uA in order to generate 
maximal rates of responding. When responding stabilized under these conditions the mice 
progressed to the three component sessions used for rate-frequency testing. Training and 
test sessions were 70 minutes in duration, divided into three 10-min response components 
separated by two 20-min timeouts. The timeout periods served as pretreatment windows 
prior to the second and third ICSS response components. Vehicle or air was administered 
prior to the second component during the first 20-min timeout. Drugs were injected or 
inhalant exposures initiated during the second 20-min timeout. In this manner baseline 
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control ICSS data (second response component) as well as test data (third response 
component) could be generated within the same subject on the same test day. Treatment 
exposures of inhalants initiated at the start of the second timeout continued through the 
third response component resulting in 30 minutes of total inhalant exposure. Response 
components were signaled by the illumination of the chamber house light. During initial 
training, each active lever press during the 10-min response components delivered a 500 
ms pulse train of pulses at a frequency of 158 Hz. After responding under the multiple 
component schedule stabilized animals were transitioned to sessions in which the 
frequency available for self-stimulation began at 158 Hz and decreased each min thereafter 
by 0.05 log units ending at 56 Hz on the last min of each component. After behavior again 
stabilized, as defined by consistent response rates ≥30 responses per minute and lever 
pressing for at least four self-stimulation frequencies of the rate-frequency curve, testing 
began. At any point in the progression of training, animals which failed to respond reliably 
were removed from the study and replaced.  
Toluene concentrations of 480, 1360, 2900, 3300 and 5000 parts-per-million (PPM) 
were examined. Nitrous oxide concentrations of 5, 20, 40, 60 and 80% combined with 
oxygen were also examined in an identical exposure design. Trichloroethane was tested at 
doses of 500, 1000 and 4000 PPM. R134a was tested at concentrations of 2.5, 5, 10 and 
20%. Isoflurane was tested at 0.25, 0.5, 1 and 2%. Due to the rapid onset of pronounced 
effects of R134a and isoflurane, a 5-minute pretreatment window was utilized. When 
spectrophotometric methods were unavailable to measure inhalant concentration within the 
chambers, approximate concentrations of inhalant within the chambers were derived using 
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the equation C = C0 (1-e
(-Q/V*t)), where C0 is final concentration, Q is he flow rate of the 
mixed gas, V is the volume of the chamber, and C is the current concentration as a function 
of time (Figure 1b).  
Sessions in which injected drugs were given were identical to inhalant test sessions 
with the exception that following the second response component the mice were given an 
IP injection of drug. Cocaine was tested at doses of 3, 10, and 18 mg/kg and diazepam was 
tested at doses of 0.3, 1, 3, 6 and 10 mg/kg. Inhalant concentrations and test drug doses 
were generally tested in an ascending order. In mice which advanced most rapidly through 
testing it was sometimes necessary to then test lower doses/concentrations to adequately 
characterize the full dose/concentration-effect curve. The ascending dose series was then 
updated for subsequent subjects. Upon completion of a dose/concentration-effect curve, 
subjects were assigned to the next planned experimental condition requiring additional 
subjects. Drug naïve subjects which replaced those animals lost to electrode failures or 
other causes were counterbalanced across test conditions with subjects with previous drug 
exposure to ensure that individual conditions contained similar numbers of naïve and 
experienced subjects. 
Progressive Ratio ICSS Procedure 
 Following completion of rate frequency testing, drugs and inhalants that showed 
facilitation procedure were then transitioned to a chain PR/FR schedule (Depoortere R et 
al, 1999). Under the PR/FR schedule, the number of lever-presses required to increment 
the schedule was increased after each completed component. The PR step-size was 
increased according to an exponential step size function (5* e
(trial# * 0.1)
- 5) (Sharma et al, 
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2012). After each PR was completed the animal received five, 500 ms ICSS pulse trains 
over five seconds and then entered a second component in which the next ten FR1 
responses were each reinforced by one 500 ms ICSS pulse train. Following the completion 
of the FR1 component the PR value incremented to the next higher ratio value and the 
PR/FR sequence repeated until a PR requirement was not completed within 6 min, 
terminating the session. During PR/FR training and testing the ICSS frequency was fixed 
at 158 Hz and the current amplitude for each mouse was the same as that used in the rate 
frequency procedure. Concentrations of 100, 480, 1360, and 2900 ppm toluene and 20, 40 
and 80% nitrous oxide combined with oxygen were administered 20 min prior to and for 
the duration of the PR/FR session. Diazepam was tested at doses of 0.3, 1, 3, and 6 mg/kg 
administered 15 min prior to the start of the PR/FR session. Cocaine was tested at doses of 
3, 10 and 18 mg/kg administered 5 min prior to the start of the PR/FR session. 
 
Quantification of Exposure Concentrations and Inhalant Blood Levels: 
Blood toluene concentrations were determined by submandibular blood sampling 
following 20 min of exposure to 480, 1360, 3300, and 5000 ppm toluene and after 30 
minutes’ exposure to 3300 ppm. The headspace gas chromatography analytical methods 
were similar to those previously reported (Shelton and Nicholson, 2010, 2012; Shelton, 
2009). A mixture of naïve mice and mice that failed to reach criteria to be useful in the 
rate-frequency procedure were repurposed for the blood toluene concentration sampling 
from the dynamic chamber exposure system. For each subject, two to three blood sample 
replicates were utilized and multiple subjects were used for each concentration. Toluene 
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exposure conditions prior to the blood sampling were identical to the dynamic exposure 
ICSS session except that subjects did not engage in ICSS behavior and were confined to 
the operant chamber. Following the set amount of time in the dynamic chamber exposure 
each subject was tightly restrained and approximately 0.1 mL of blood was obtained 
utilizing the submandibular vascular bundle via a 5 mm lancet. Subject’s blood droplets 
were quickly captured in a micro collection tube containing EDTA (BD lavender top 
Microtiter). Following capture of the blood collected sample, the subject was isolated and 
pressure was applied to the incision to stop further blood loss. The EDTA tube was then 
briefly agitated and a 20 ul blood sample was then removed and placed into a 20 ml 
headspace vial to which 960 ul of type 1 ultrapure water and 20 ul of o-xylene internal 
standard had been previously added. The blood samples were then immediately tested for 
toluene concentration using a Hewlett Packard model 5890A gas chromatograph (GC) 
equipped with a flame ionization detector, 2.5 meter 10% TCEP 100/120 Chromosorb 
PAW column (Restek, Bellefonte, PA) and CTC Combi-Pal headspace auto sampler. The 
GC parameters were: 5 min sample incubation at 90C, headspace sample volume 1.25 ml, 
7 min sample run time, injector temp 200C, oven temp isothermal 110C, detector temp 
200C, helium carrier gas flow rate 30 ml/min, FID hydrogen flame flow rate 25 ml/min 
and FID air flow rate 400 ml/min. Data were collected and analyzed by Clarity GC 
software (Apex data systems, Prague, CZ) using a linear regression analysis with no 
weighting. A 7-point calibration curve preceded the analysis of blood samples and quality 
control toluene standards were interspersed with each set of blood samples. Blood toluene 
concentrations were calculated by the internal standard method. Up to 3 replicates were 
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analyzed from each animal and averaged if sufficient blood was collected. Each blood 
concentration data point represents a mean (±SEM) toluene blood concentration (ug/ml) 
generated from at least 3 mice. 
 
Data Analysis 
 In the three component procedure, data from the first 10-min response component 
was discarded as it has been shown to exhibit more variability compared to subsequent 
components (Negus and Miller, 2014). Stimulations earned during each 1-min trial of the 
second 10-min air/vehicle exposure control component were compared to the equivalent 
trial in the third 10-min drug test component. For each mouse, data from each trial were 
expressed as a percentage of the number of stimulations in the 1-min trial with the greatest 
number of responses, regardless of frequency, in the second baseline component. The 
values are reported as percentage of the maximum control responses (%MCR). This data 
normalization procedure allowed grouping of the data across subjects despite differences in 
individual maximum response rates. Data from the second control and third test component 
were compared individually for each drug dose or inhalant concentration by two-way 
within subject repeated measures analysis of variance (ANOVA). GraphPad version 7.0 for 
Windows (La Jolla, CA) was used for all analyses. Significant (p < 0.05) main effects and 
interactions were subsequently examined by the Two-stage step-up method of Benjamini, 
Krieger and Yekutieli to compare identical frequencies across the control and test 
components (Benjamini et al, 2006). This procedure for correcting for the multiple 
comparisons problem is more powerful than Bonferroni type corrections that provide for a 
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strong correction for the overall family-wise error rate (Glickman et al, 2014). This 
procedure gains power by assuming that either all comparisons that are being made either 
have a positive-dependence on each other (i.e. comparison of points along parallel curves) 
or that each comparison is independent of every other comparison. It does this by a two 
stage procedure that first controls for the false discovery rate of the hypotheses being tested 
by examining the overall P values of the comparisons being made in order to estimate the 
proportion of the null hypotheses that are actually true. The algorithm then uses the 
proportion of null hypotheses that are actually true to set the cutoff limit for when a P 
value is sufficiently low to be called a true discovery. 
 Rate-frequency data were also analyzed to calculate M50 values for the baseline 
and treatment conditions in the rate frequency curve to collapse data for summary 
statistics. If mean response rates did not differ across subjects within a dose-response curve 
an average was utilized to form a common reference point for statistical comparison. M50 
values represent the interpolated frequency that maintains 50% maximum response rates. 
The estimated linear portion of the rate-frequency curve from 20%-80% of %MCR was 
analyzed for each subject using a least-squares regression line of best fit to estimate M50. 
Group treatment condition M50s were then compared by student’s paired t-test to group 
vehicle control baseline to determine whether the %M50 shift was significant (p < 0.05).  
 To further elucidate the generality of procedures that can produce 
significant facilitation, compounds which showed significant facilitation in the rate 
frequency procedure were then also tested in the progressive ratio procedure (note: further 
testing with TCE was not possible due to production and importation bans in the United 
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States). In this procedure test condition breakpoint data were normalized by expressing 
them as a change in breakpoint from each subject’s baseline control breakpoint. The 
average breakpoint of two vehicle (air or saline) test sessions was defined as the baseline 
breakpoint. Change in breakpoint resulting from drug exposure was calculated by 
subtracting the baseline breakpoint from the test breakpoint for each subject. Group mean 
changes in breakpoints were then compared across drug or inhalant doses by a one-way 
within subject repeated measures ANOVA. Significant (p < 0.05) main effects were 
examined by Holm-Sidak post-hoc tests comparing changes in breakpoint for drug and 
inhalant exposure conditions to either air or saline. 
One of the major goals of my thesis was to develop and characterize the ICSS 
procedure as a method to assess the reward-related effects of inhalational delivery of 
abused inhalants in mice. To confirm that the ICSS procedure I adapted from rats was 
sensitive to assessing reward-related effect in mice I initially examined cocaine which has 
been established to produce robust facilitation of ICSS. I then examined the effects of 
toluene, nitrous oxide, isoflurane, R134a, and trichloroethane on ICSS to determine the 
sensitivity of the procedure to detect the reward-related effects of a diverse group of 
inhalants. Further I wanted to compare the effects of the inhalants to a more 
pharmacologically understood abused drug with some known similarities in their 
pharmacological effects. Given that toluene, trichloroethane, isoflurane and nitrous oxide 
have all been shown to act with varying specificity as positive GABAA modulators in vitro 
and have similar anxiolytic effects in vivo I chose to examine diazepam as a reference 
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compound (Bowen et al, 1996; Cruz et al, 1998; Emmanouil et al, 1994; Hapfelmeier et al, 
2000). The data from each of these studies are presented in the subsequent sections. 
 
Results 
Rate Frequency Procedure 
 Doses of 3, 10 and 18 mg/kg cocaine significantly facilitated ICSS (Figure 2a-c). 
There was a significant main effect of 3 mg/kg cocaine [F (1,10) = 15.68, p = 0.0027] 
(Figure 2a) on ICSS responding but no drug x frequency interaction [F (1,10) = 1.121, p = 
0.3561], but was significantly facilitated at 9 of 10 frequencies. There was a significant 
main effect [F (1, 10) = 34.05, p = 0.0002)] and a significant drug x frequency interaction 
[F (9, 90) = 2.480, p = 0.0141] of 10 mg/kg cocaine on %MCR (Figure 2b) with 
responding at 8 frequencies significantly increased over control. There was a significant 
main effect [F (1, 10) = 28.09 , p = 0.0003] and a significant drug x frequency interaction 
[F (9, 90) = 4.278, p = 0.0001] of 18 mg/kg cocaine on %MCR (Figure 2c) with the 7 
lowest frequencies showing significantly higher rates of responding compared to control. 
Cocaine doses of 3 mg/kg [t (10) = 2.961, p = 0.0143] and 10 mg/kg [t (10) = 3.101, p = 
0.0112] significantly lowered the M50 (table 2). A M50 value for 18 mg/kg cocaine could 
not be calculated as responding was too robustly increased across the ICSS frequency 
curve and responding never dropped below 50% of MCR to permit the analysis. 
 In the rate frequency procedure 0.3 mg/kg diazepam failed to significantly alter 
ICSS (Figure 3a). 1 and 3 mg/kg diazepam significantly facilitated ICSS (Figure 3b-c). 6 
and 10 mg/kg significantly depressed ICSS responding (Figure 3d-e). There was a 
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significant main effect of 1 mg/kg diazepam [F (1, 8) = 5.478, p = 0.0474] (Figure 3b) but 
no drug x frequency interaction [F (9, 72) = 1.374, p = 0.2160] with 6 frequencies 
significantly elevated over baseline. There was a significant drug x frequency interaction 
[F (9, 72) = 3.473, p = 0.0013] of 3 mg/kg diazepam on %MCR (Figure 3c) with 
responding at 6 of the lowest frequencies significantly increased over control. There was a 
significant drug x frequency interaction of 6 mg/kg diazepam on %MCR [F (9, 72) = 
4.139, P = 0.0003] (Figure 3d) with the highest frequency showing a significant decrease 
of ICSS responding compared to control. There was a significant drug x frequency 
interaction of 10 mg/kg diazepam on %MCR [F (9, 72) = 2.624, P = 0.0111] (Figure 3e) 
with the 2 highest frequencies showing a significant decrease of ICSS responding 
compared to control. Diazepam doses of 1 mg/kg [t (8) = 4.314, p = 0.0026] and 3 mg/kg [t 
(8) = 3.406, p = 0.0093] also significantly lowered M50 values (table 2).  
480 ppm toluene (Figure 4a) failed to significantly facilitate ICSS while 
concentrations of 1360-5000 ppm toluene (Figure 4b-f) all produced significant effects on 
ICSS. There was a significant main effect (F (1, 10) = 16.51, p = 0.0023) and significant 
interaction [F (9, 90) = 7.134, p < 0.0001] of 1360 ppm toluene on ICSS with 8 of 10 
frequencies showing significantly greater %MCR (Figure 4b) compared to control. There 
was significant interaction [F (9, 90) = 2.455, p = 0.0151] of 2000 ppm toluene on ICSS 
with 9 of 10 frequencies showing significantly greater %MCR (Figure 4c) compared to 
control.  
There was a significant interaction of 2900 ppm toluene [F (9, 90) = 5.200, p < 
0.0001] on %MCR (Figure 4d) with 3 of the lowest frequencies showing a significantly 
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enhancement of ICSS responding compared to control. There was a significant interaction 
of 3300 ppm toluene [F (9, 90) = 7.136, p < 0.0001] on %MCR (Figure 4e) on ICSS with 
the two highest frequencies demonstrating a significant depression and the two lowest 
frequencies a significant enhancement of ICSS responding compared to control. The 5000 
ppm toluene concentration produced a significant interaction [F (9, 90) = 8.499, p < 
0.0001] on %MCR (Figure 4f) with 9 of 10 frequencies exhibiting a significant 
suppression of ICSS responding compared to control. Toluene concentrations of 1360 ppm 
[t (10) = 4.946, p = 0.0006] (table 2) and 2000 ppm significantly decreased the M50 [t (10) 
= 3.652, p = 0.0045] (table 2). 
Concentrations of 5 and 20% nitrous oxide failed to significantly alter responding 
for ICSS (Figures 5a-b). Nitrous oxide concentrations of 40, 60 and 80% all significantly 
altered ICSS responding (Figures 5c-e). There was a significant interaction [F (9, 54) = 
2.400, p = 0.0228] of 40% nitrous oxide on ICSS with 2 of 10 frequencies showing 
significantly greater %MCR than control (Figure 5c). The 60% nitrous oxide concentration 
produced a significant interaction [F (9, 54) = 3.101, p = 0.0045] with the highest 
frequency showing a significantly lower %MCR than control (Figure 5d). The highest, 
80% nitrous oxide concentration produced a significant interaction [F (9, 54) = 9.944, p < 
0.0001] on %MCR (Figure 5e) with 5 of 10 frequencies showing suppressed rates of ICSS 
responding compared to control. The 40% nitrous oxide also significantly lowered the M50 
[t (6) = 3.771, p = 0.0093] (table 2). 
Isoflurane concentrations of 0.25, 0.5, and 1% failed to significantly alter ICSS 
responding (Figures 6a-c). Isoflurane at 2% significantly decreased responding for ICSS 
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(Figure 6d). There was a significant interaction [F (9, 36) = 4.277, p = 0.0008] of 2% 
isoflurane on ICSS with 6 of 10 frequencies showing significantly depressed %MCR than 
control (Figure 6d). Isoflurane did not shift M50s (table 2). 
A R134a concentration of 2.5% failed to alter ICSS responding (Figure 7a). 
Concentrations of 5, 10 and 20% R134a significantly and concentration-dependently 
depressed ICSS responding (Figures 7b-d). There was a significant main effect [F (1, 6) = 
17.74, p = 0.0056] of 5% R134a on ICSS with 2 of 10 frequencies showing significantly 
depressed %MCR compared to control (Figure 7b). There was a significant main effect [F 
(1, 6) = 13.3, p = 0.0107] of 10% R134a on ICSS with 1 of 10 frequencies showing 
significantly depressed %MCR compared to control (Figure 7c). The 20% R134a 
concentration produced a significant interaction [F (9, 54) = 12.06, p < 0.0001] on %MCR 
(Figure 7d) with 7 of 10 frequencies showing suppressed rates of ICSS responding 
compared to control. R134a did not shift M50s (table 2). 
TCE concentrations of 500 and 1000 PPM failed to alter ICSS responding (Figures 
8a-b). A concentration of 4000 PPM TCE produced a significant interaction [F (9, 27) = 
3.171, p < 0.0001] on %MCR (Figure 8c) with 5 of 10 frequencies showing facilitation of 
ICSS responding compared to control. The 4000 PPM TCE also significantly lowered the 
M50 [t (6) = 2.691, p = 0.0360] (table 2). 
Progressive Ratio Procedure 
Cocaine significantly increased progressive-ratio breakpoint [F (1.280, 7.681) = 
9.534, p= 0.0126] (Figure 9a). Doses of 10 and 18 mg/kg cocaine significantly (p < 0.05) 
increased breakpoint compared to saline control. Diazepam significantly increased [F 
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(2.657, 18.60) = 4.447, p = 0.0189] progressive-ratio breakpoint (Figure 9b). The 3 mg/kg 
diazepam dose significantly increased breakpoint compared to saline control. Toluene 
(Figure 9c) also significantly increased breakpoint [F (2.462, 17.23) = 7.964, p = 0.0023]. 
The 1360 ppm toluene concentration significantly increased breakpoint compared to air 
control. Nitrous oxide (Figure 10d) significantly decreased ICSS breakpoints [F (1.719, 
10.32) = 5.400, p = 0.0282]. Breakpoint at both the 40% and 80% nitrous oxide 
concentrations significantly (p < 0.05) were significantly lower than air control.  
Inhalant Blood Levels of Toluene 
There was a linear relationship between toluene vapor exposure concentration and 
toluene blood concentration (Figure 10). The lowest exposure concentration of 480 ppm 
toluene produced a mean blood concentration of 3.7 ug/ml after 20 min of exposure 
increasing to 61.2 ug/ml at the highest, 5000 ppm toluene exposure concentration. To 
determine the extent to which toluene blood concentration may have increased during the 
third ICSS response component I also examined toluene blood levels after 30 min of 
exposure to the intermediate concentration of 3300 ppm. Exposure to 3300 ppm toluene 
for 30 min resulted in about ~15% increase in blood toluene concentration compared to 
exposure for 20 min (Figure 10a).  
Effect of duration of toluene exposure on magnitude of ICSS facilitation 
In the prior studies, a toluene pretreatment exposure time of 20 min prior to the 
start of ICSS testing was utilized to maintain some consistency with prior toluene drug 
discrimination studies in the laboratory (Shelton and Nicholson, 2013; Shelton, 2007). 
However, it was possible that pretreatment time may have influenced the magnitude of the 
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facilitation produced by toluene. Therefore, I conducted an additional study utilizing 
pretreatment durations of 5 and 15 min to explore the relationship between toluene 
pretreatment time and the start of the ICSS test session to explore the relationship on 
toluene’s ability to facilitate ICSS relative to the longer duration exposures of 20 min. Five 
minutes of exposure to 1000 ppm toluene (Figure 10b a) failed to significantly facilitate 
ICSS when it was administered 5 min prior to and throughout the ICSS test session. The 
main effect of treatment was [F (1, 6) = 1.166, P=0.3217] and the interaction was [F (9, 54) 
= 1.367, P=0.2261]. Fifteen minutes of exposure to 1000 ppm toluene (Figure 10b b) also 
failed to significantly facilitate ICSS when it was administered 15 min prior to and 
throughout the ICSS test session. The main effect of treatment was [F (1, 6) = 0.4595, 
P=0.5231] and the interaction was [F (9, 54) = 1.339, P=0.2391]. 
There was a significant main effect (F (1, 6) = 32.02, p = 0.0013) and interaction [F 
(9, 54) = 6.904, p < 0.0001] of five minutes of exposure to 3300 ppm toluene on ICSS with 
8 of 10 frequencies showing significantly greater %MCR (Figure 10b c) compared to 
control. There was a significant main effect (F (1, 6) = 7.532, p = 0.0335) and interaction 
[F (9, 54) = 4.933, p < 0.0001] of 15 minutes of exposure 3300 ppm toluene on ICSS with 
7 of 10 frequencies showing significantly greater %MCR (Figure 10b d) compared to 
control and the highest frequency of 156 Hz showing significantly lower %MCR than 
control.  
Five minutes of exposure to 5600 ppm toluene (Figure 10b e) failed to significantly 
facilitate or depress ICSS. There was no main effect [F (1, 6) = 2.338, P=0.1771] or 
interaction [F (9, 54) = 0.6231, P=0.7721]. Fifteen minutes of exposure to 5600 ppm 
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toluene significantly affected responding for ICSS. There was a significant main effect (F 
(1, 6) = 12.64, p = 0.0120) and significant interaction [F (9, 90) = 3.519, p = 0.0017] of 
5600 ppm on %MCR (Figure 4d) with the 4 highest frequencies demonstrating a 
significant depression compared to control.  
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Table 2 
Drug Dose/Conc. %M50 Shift (±SEM)     %Max Rate (±SEM) 
Diazepam 0.3 mg/kg  6.0 7.5  88.9 9.2 
 1 mg/kg ↓ -18.9 4.0  117.9 8.8 
 3 mg/kg ↓ -19.9 5.4  110.8 8.6 
 6 mg/kg  -9.3 7.6  93.9 12.5 
 10 mg/kg   NC   47.0 20.9 
        
Cocaine 3 mg/kg ↓ -10.2 3.4 ↑ 110.9 4.2 
 10 mg/kg ↓ -19.3 5.3  106.0 5.9 
 18 mg/kg  NC  ↑ 122.3 9.0 
        
Nitrous Oxide 5%  2.7 9.4  102.8 7.3 
 20%  1.6 4.3  101.2 5.8 
 40% ↓ -16.0 4.2  94.7 4.6 
 60%  -4.4 6.9 ↓ 82.4 3.4 
 80%  NC  ↓ 71.7 4.1 
        
Toluene 480 PPM  -4.6 5.2 ↑ 107.3 5.2 
 1360 PPM ↓ -26.7 6.0  99.6 5.3 
 2000 PPM ↓ -21.6 5.7  97.5 5.7 
 2900 PPM  -11.9 8.6  88.4 4.9 
 3300 PPM  NC  ↓ 79.9 7.2 
 5000 PPM  NC  ↓ 42.4 7.2 
R134a 2.5%  3.2 1.3  99 5.3 
 5%  7.6 1.4  84 4.4 
 10%  8.6 1.5  92.1 2.5 
 20%  NC  ↓ 18.8 12.6 
Isoflurane 0.25%  4.2 4.6  100.3 5.4 
 0.5%  -0.2 4.3  100.7 4.1 
 1.0%  -0.6 8.6  100.2 9.8 
 2.0%  NC  ↓ 49.0 13.9 
Trichloroethane 500 PPM  1.8 5.9  104.3 11.8 
 1000 PPM  -7.1 5.7 ↑ 125.3 9.4 
 4000 PPM ↓ -26.4 12.6  100.5 6.0 
        
Table 2: Percentage M50 shift and percentage maximum rate of baseline for Diazepam (n=9), 
Cocaine (n=11), Nitrous Oxide (n=7), Toluene (n=11), R13a (n=7). Isoflurane (n=5) and 
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Trichloroethane (n=4).  ↑↓indicate direction of significance from vehicle baseline (p < 0.05). 
NC, not calculated. 
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Figure 1a 
 
 
 
 
 
 
Figure 1a: Schematic representation of the experimental apparatus constructed to expose 
mice to toluene vapor. A dynamic gas mixer controlled the flow rate of compressed air 
directed through a 1L glass bubbler container partially filled with liquid toluene. The 
toluene vapor laden air stream thus generated was then proportionally mixed with a clean 
air stream before being directed into a 20L exposure cubicle housing an operant 
conditioning chamber. Effluent from the exposure chamber was routed through an IR 
spectrometer connected to a computerized chart recorder to monitor real-time exposure 
chamber concentrations. N2O and R134a delivery were identical except that nitrous oxide 
gas or R134a and medical oxygen were delivered from compressed cylinders and the 
bubbler was not utilized. Isoflurane was delivered via an aesthetic gas vapor machine. 
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Figure 1b 
 
Figure 1b: Measure (Toluene) and derived concentrations of inhalants (N2O, Isoflurane, 
R134a). Red represents the rising concentration to steady state levels and green represents 
time when subjects were tested in ICSS. In the case of nitrous oxide, R134a, and 
isoflurane, burst kinetic concentrations were used to rapidly speed up the delivery of 
inhalants in that for a brief period in the beginning a larger concentration was pumped into 
the chambers before switching to the steady-state concentration being examined.  
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Figure 2 
 
Figure 2: Mean (±SEM) percent maximal control ICSS response rate following 20-minute 
pretreatment with I.P. cocaine. Red square symbols represent the cocaine treatment 
condition and white circle symbols the saline control condition. (a) 3 mg/kg cocaine (b) 10 
mg/kg cocaine (c) 18 mg/kg cocaine. Filled black squares denote significant differences 
compared to saline control (p < 0.05).  
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Figure 3 
 
Figure 3: Mean (±SEM) percent maximal control ICSS response-rate following 
pretreatment with I.P. diazepam. Red square symbols represent the diazepam treatment 
condition and white circle symbols the saline control condition. (a) 0.3 mg/kg diazepam (b) 
1 mg/kg diazepam (c) 3 mg/kg diazepam (d) 6 mg/kg diazepam (e) 10 mg/kg diazepam. 
Filled black square denotes significant differences compared to saline control (p < 0.05). 
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Figure 4 
 
Figure 4: Mean (±SEM) percent maximal control ICSS response rate following 20 minute 
of exposure to toluene vapor. Red square symbols represent the toluene vapor treatment 
condition and white circle symbols the air control condition. (a) 480 ppm toluene (b) 1360 
ppm toluene (c) 2900 ppm toluene (d) 3300 ppm toluene (e) 5000 ppm toluene. Filled 
black square denotes significant differences compared to saline control (p < 0.05). 
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Figure 5 
 
Figure 5: Mean (±SEM) percent maximal control ICSS response following exposure to 
nitrous oxide gas combined with 100% oxygen. Red square symbols represent the nitrous 
oxide treatment condition and white circle symbols the air control condition. (a) 20% 
nitrous oxide (b) 40% nitrous oxide (c) 60% nitrous oxide (d) 80% nitrous oxide. Filled 
black squares denote significant differences compared to control (p < 0.05). 
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Figure 6 
 
Figure 6: Mean (±SEM) percent maximal control ICSS response rate following 
pretreatment with exposure to isoflurane combined with 100% oxygen. Red square 
symbols represent the oxygen control treatment condition and white circle symbols the air 
control condition. (a) 0.25% isoflurane (b) 5% isoflurane (c) 10% isoflurane (d) 20% 
isoflurane. Filled black squares denote significant differences compared to control (p < 
0.05). 
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Figure 7 
 
Figure 7: Mean (±SEM) percent maximal control ICSS response rate following 
pretreatment with exposure to R134a combined with 100% oxygen. Red square symbols 
represent the R134a treatment condition and white circle symbols the air control condition. 
(a) 2.5% R134a (b) 5% R134a (c) 10% R134a (d) 20% R134a. Filled black squares denote 
significant differences compared to control (p < 0.05). 
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Figure 8 
 
Figure 8: Mean (±SEM) percent maximal control ICSS response rate following 
pretreatment with exposure to TCE. Red square symbols represent the TCE treatment 
condition and white circle symbols the air control condition. (a) 500 PPM TCE (b) 1000 
PPM TCE (c) 4000 PPM TCE. Filled black squares denote significant differences 
compared to control (p < 0.05). 
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Figure 9 
 
Figure 9: (a) Mean (±SEM) change in progressive-ratio breakpoint relative to saline 
control for 3, 10 and 18 mg/kg I.P. injected cocaine (b) Mean (±SEM) change in 
progressive-ratio breakpoint relative to saline control for 0.3, 1, 3 and 6 mg/kg I.P. injected 
diazepam (c) Mean change in progressive-ratio breakpoint relative to air control for 
exposure to 110, 480, 1360, and 2900 ppm toluene (d) Mean change in progressive-ratio 
breakpoint relative to air control for exposure to 20, 40 and 80% nitrous oxide. Filled black 
squares denote significant differences compared to vehicle control (p < 0.05). 
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Figure 10a 
 
Figure 10a: Mean (±SEM) C57BL/6J mice toluene blood concentrations measured after 20 
minutes of exposure (red square) in the dynamic chamber per exposure concentration and 
30 minutes after exposure (black diamond, 3300ppm only) (n=3-4/concentration). 
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Figure 10b 
 
Figure 10b: Mean (±SEM) % MCR following 5 or 15 min of exposure to toluene vapor. Red 
square symbols represent the toluene vapor treatment condition and white circle symbols the air 
condition. (a) 1000 ppm toluene (5 min) (b) 1000 ppm toluene (15 min) (c) 3300 ppm toluene (5 
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min) (d) 3300 ppm toluene (15 min) (e) 5600 ppm toluene (5 min) (f) 5600 ppm toluene (15 min). 
Filled black square denotes significant differences compared to control (p < 0.05). 
 
Discussion Aim 1 
 As expected, cocaine produced a robust dose-dependent facilitation across ICSS 
responding at all three tested doses. These data are in agreement with previous literature 
examining cocaine treated C57BL/6J mice in the rate frequency ICSS procedure (Fish et 
al, 2010; Straub et al, 2010). The positive GABAA allosteric modulator diazepam (Figure 
3a-d) produced a less robust effect on ICSS in the rate-frequency procedure than has 
previously been reported. The 0.3 mg/kg diazepam dose did not alter ICSS, 1 and 3 mg/kg 
doses facilitated ICSS and 6 and 10 mg/kg dose suppresses ICSS. Similarly, the 3 mg/kg 
dose of diazepam also significantly increased ICSS breakpoint in the progressive ratio 
procedure (Figure 9a). Although less robust, the data are consistent with previous ICSS 
studies in mice that utilized a different curve-shift ICSS procedure. That study in 
C57BL/6J mice showed no effect of 0.3 mg/kg diazepam and a significant facilitation of 
ICSS by 1-4 mg/kg diazepam (Reynolds et al, 2012; Straub et al, 2010). Taken together 
these data confirm that diazepam reliably facilitates ICSS in mice across multiple ICSS 
procedural variants. Overall the data with cocaine and diazepam demonstrate that the three 
component rate-frequency and progressive ratio ICSS test conditions I employed are 
sensitive to the reward-facilitating effects of abused drugs.  
The present data substantially extend the conditions under which it can be 
demonstrated that toluene will facilitate ICSS to include both the rate-frequency and 
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progressive-ratio ICSS procedure variants. While more limited in scope, the data also 
describe the effects of TCE in the rate frequency procedure. In contrast to cocaine which 
facilitated ICSS across the entire tested dose range, toluene produced a complex pattern of 
rate increasing and decreasing effects more robust than, but generally similar to the second 
positive control diazepam. Specifically, intermediate toluene concentrations facilitated 
ICSS in both the rate frequency and the PR procedure. Moderately high toluene 
concentrations produced a biphasic effect, facilitating ICSS at low frequencies and 
suppressing ICSS at high frequencies while having no effect on PR responding. The 
highest toluene concentration suppressed ICSS regardless of stimulation frequency in the 
rate-frequency procedure.  
Interestingly, the duration of toluene pretreatment prior to testing appeared to 
strongly influence the degree of ICSS facilitation it engendered. The trend for this 
appeared to favor a higher abuse-like concentration delivered over a shorter amount of 
time. It was found that 5 minutes of exposure to 3300 ppm toluene produced the most 
robust increases in ICSS facilitation (Figure 10b c) and parallels the results of ethanol in 
ICSS where the most reinforcement enhancing effects are observed when responding for 
ICSS is in close temporal proximity to the initial delivery of the ethanol (Fish et al, 2010).  
This robust facilitation was a necessity for attempting to utilize ICSS to examine 
ligands to probe contributions from particular receptor systems and subtypes.  
Similar to past studies in which volatilized TCE was given to subjects in alternative 
ICSS reinforcement-enhancement models (Bespalov et al, 2003; Yavich and Zvartau, 
1994), TCE also produced reward-like effects in the rate-frequency procedure at 4000 
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ppm. Unfortunately, while TCE remains a major inhalant of abuse in some countries, the 
United States Environmental Protection Agency has banned import and production in 
United States. Therefore, the quantity of TCE available did not permit further investigation 
at higher concentrations in the rate frequency procedure testing in the chain PR/FR10 
procedure. However, like toluene, higher concentrations of TCE are associated with 
production of sedative-like effects in locomotor activity (Bowen and Balster, 1998) and 
producing pronounced rate deceasing effects in operant behavior (Moser and Balster, 1986; 
Shelton, 2009). 
In ICSS, an enhancement of responding for stimulation following drug 
pretreatment is usually interpreted as a facilitation of brain reward circuitry (Wise et al, 
1992). In contrast, a depression of ICSS responding by a test drug has multiple 
interpretations (Carlezon and Chartoff, 2007). The first is that the pretreatment drug is 
producing anhedonic-like effects, reducing the subject’s sensitivity to the reinforcing 
effects of brain stimulation. For example, it has been shown that the kappa-opioid receptor 
agonist U69,593 produces a characteristic anhedonic-like effect when administered alone 
as well as blocking the reinforcement enhancing effects of ICSS produced by cocaine 
(Tomasiewicz et al, 2008). It is unclear if toluene is producing anhedonic-like effects in the 
present study although it is possible given previous data demonstrating that extended 
exposure to 1650-3300 ppm toluene vapor for 4 hours can produce a conditioned taste 
aversion (Miyagawa et al, 1984). However, in a conditioned place preference study, a 
significant preference for an environment paired with a shorter 30 minutes of exposure to 
2000 and 3000 ppm toluene was observed while exposure to 5000 ppm toluene failed to 
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produce a place preference, possibly indicating the recruitment of anhedonic-like effects at 
this higher concentration (Lee et al, 2006). Interestingly, at a concentration of 5600 ppm 
toluene, I observed a significant depression in responding in the ICSS rate-frequency 
procedure which could be an indicator to anhedonic effects. 
A second interpretation of depression of ICSS responding is that the test drug 
interferes with the ability of the subjects to physically perform the operant. For example, 
the sedative zolpidem has been shown to decrease operant performance in ICSS in the rate 
frequency procedure (Reynolds et al, 2012). It is certainly possible that this could be 
responsible for the suppression of ICSS at 5600 ppm toluene given that exposure to 15 min 
of 8000 ppm toluene vapor suppresses locomotor activity in C57BL/6J mice (Bowen et al, 
2010). Exposure to concentrations of toluene vapor greater than 2000-3000 ppm suppress 
operant responding under fixed ratio as well as fixed interval schedules in mice (Moser and 
Balster, 1985; Bowen and Balster, 1998) suggesting that operant responding is even more 
sensitive to motor incoordination effect of toluene than locomotor activity. However, in the 
present study the effect of toluene at 3300 ppm was ICSS frequency dependent with 
responding at low ICSS frequencies increased by toluene whereas responding was 
suppressed at high ICSS frequencies. This effect could have been due to motor 
incoordination manifesting itself primarily at the high frequencies which supported the 
greatest rates of responding but it may also suggest a classic rate-dependent effect (Dews, 
1977). This latter interpretation is possible, although under fixed interval schedules for 
food maintained responding response-rate increasing effects of toluene in mice are either 
not apparent (Bowen and Balster, 1998) or extremely modest (Moser and Balster, 1986). 
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Additional studies will be necessary to further explore these possibilities as they relate to 
ICSS performance.  
The facilitation of ICSS by nitrous oxide was much less pronounced than that 
produced by toluene, diazepam or cocaine. In the rate-frequency procedure 40% nitrous 
oxide facilitated ICSS, although only significantly so at two intermediate stimulation 
frequencies (Figure 5b). The 60% and 80% nitrous oxide concentrations suppressed ICSS 
in the rate-frequency procedure and both 40% and 80% nitrous oxide suppressed PR 
responding. Prior preclinical studies examining the rewarding effects of nitrous oxide have 
also have generated conflicting results. Squirrel monkeys self-administered a mixture of 
60% N2O / 40% O2 (Wood et al, 1977). However, in a rat place conditioning and self-
administration study, repeated pairings of an environment with 40 minute of exposures to 
30% and 60% nitrous oxide produced a conditioned place aversion and inconsistent results 
in self-administration (Ramsay et al, 2003). Human self-administration and subjective tests 
of N2O exposure have been equally divergent among healthy subjects. In human subjects 
given the option to self-administer 30% N2O, oxygen vehicle or air, but blinded to the 
identity of their choice, 5 of 12 subjects consistently chose N2O, 4 consistently avoided 
N2O, and 3 subjects were divided between N2O and the oxygen/placebo alternatives 
(Walker and Zacny, 2001). Taken together the present results and previous studies suggest 
that the rewarding effects of nitrous oxide at least as measured by self-administration, 
ICSS and conditioned place preference are at best fairly modest compared to other drugs of 
abuse including other inhalants such as toluene.  
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In contrast to toluene, both isoflurane and R134a produced no facilitation of ICSS 
at lower concentrations, coupled with a strong decrease in ICSS responding at higher 
concentrations. These findings suggest these compounds may have limited abuse-liability. 
This finding is, however, at odds with demonstrated evidence of abuse of both compounds 
in humans (Koehler and Henninger, 2014; Kuhlman et al, 1993; Pavlic et al, 2002; Ritchie 
et al, 2001). It is possible that like nitrous oxide, there is a limited window where 
facilitation of ICSS by isoflurane and R134a would be most pronounced. It may be the 
case that the concentration necessary to produce facilitation was missed as the rate-
decreasing effects for isoflurane and R134a occurred over a very narrow range in the 
curve, particularly in the case of isoflurane. Indeed, the observation with 1% isoflurane at 
the end of the session was the appearance of sedative-like effects in some subjects. The 
onset of sedation in some subjects may have masked facilitation produced by isoflurane for 
other subjects effectively producing a null group effect as is seen in the 1% isoflurane 
exposure (a mean of facilitation and sedative effects across subjects). The variability of 
individual subjects to sedative effects that interfere with operant responding has also been 
observed in drug discrimination with diazepam (Shelton and Nicholson, 2012). It may 
therefore be useful to examine ICSS dependent measures utilizing an alternative 
concentration-response curves where subjects are excluded that show strong signs of 
sedation. 
In summary, the findings indicate that toluene robustly facilitates progressive ratio 
ICSS breakpoint and enhances the reinforcing efficacy of low to mid-range frequencies of 
stimulation in the rate-frequency procedure. TCE also enhances the reinforcing efficacy of 
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low to mid-range frequencies of stimulation in the rate-frequency procedure. In contrast 
N2O only weakly facilitates ICSS responding in the rate-frequency procedure and 
produced a concentration dependent suppression of ICSS breakpoint in the chain PR/FR10 
procedure. These results suggest that while demonstrating some reinforcement enhancing 
effects, N2O may also produce effects which more strongly compete with behaviors 
necessary to progress in the PR procedure relative to rate-frequency schedule. In the rate-
frequency procedure every lever-press results in some degree of stimulation, the 
production of interfering behaviors may have a much more limited effect on response 
output as compared to the progressive ratio procedure which requires successively greater 
numbers of responses in the absence of reinforcer presentation. Lastly, isoflurane and 
R134a produced only a concentration dependent depression of ICSS in the rate frequency 
procedure. 
Given the relative difficulty of quantifying the reinforcing effects of inhaled 
substances using standard measures of drug reinforcement, developing alternative 
procedures is important for advancing knowledge in the area. The data with toluene, TCE 
and nitrous oxide in mice suggest that ICSS is a viable method to probe the 
neurobiological mechanisms underlying the rewarding effects of abused inhalants. 
However, further examination of additional ICSS procedural parameters that might 
generate data entirely consistent with the known abuse liability of individual inhalants 
should be further investigated. 
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Aim 2: Determine the role of GABAA receptors in inhalant facilitated ICSS 
Materials and Methods 
Subjects 
 A total of 17 and 16 adult male C57BL/6J mice (Jackson Laboratory, Bar Harbor, 
Maine) were used for the ICSS and microdialysis experiments, respectively. Mice were 
individually housed under a 12h light/dark cycle and tested during the light phase of the 
cycle. Laboratory chow (Harlan, Madison, WI) and water were available ad libitum except 
during experimental sessions. All procedures were approved by the Institutional Animal 
Care and Use Committee of Virginia Commonwealth University and were in accordance 
with NIH guidelines (National Research Council, 2011). For the ICSS studies, not all 
subjects were tested in all conditions. Order effects were controlled by separating test 
sessions by at least 36 hours and counterbalancing naive subjects with drug experienced 
subjects across experiments. Dose response curves and antagonism studies were tested in 
ascending dose order to minimize the effects of repeated exposure. 
Compounds 
 Toluene was purchased from Fisher Scientific. D-methamphetamine hydrochloride 
was obtained from the National Institute on Drug Abuse Drug Supply Program and 
prepared in 0.9% sterile saline. Diazepam was obtained in an injectable commercial 
formulation. Flumazenil was obtained from Sigma-Aldrich (St. Louis, MO). Ro15-4513 
was obtained from Tocris Bioscience (Minneapolis, MN). Flumazenil, Ro15-4513 and 
diazepam were prepared in a 45% hydroxypropyl-β-cyclodextrin (HP-BCD) vehicle 
(Sigma-Aldrich, St. Louis, MO). 
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Dynamic Vapor Exposure System and Testing Apparatus 
The dynamic inhalant vapor exposure/ICSS system utilized has been described 
previously (Tracy et al, 2014). Briefly, toluene vapor was produced using a microprocessor 
controlled vapor generator and routed into acrylic cubicles containing two-lever operant 
conditioning chambers. Toluene concentrations within each chamber were verified by 
headspace gas chromatography. ICSS stimulation and schedule controlled delivery were 
provided by commercially-available components (Med-Associates, St. Albans, VT). 
Concentrations of toluene produced the chamber are shown in Figure 11. 
ICSS Surgical Procedure 
Mice were implanted under isoflurane and morphine (0.2 mg/kg s.c.) anesthesia 
with bipolar electrodes (Plastics One, Roanoke, VA) directed at the right medial forebrain 
bundle (Paxinos and Franklin, 2001). Coordinates relative to bregma were: -1.5 anterior-
posterior, 1.0 medial-lateral, and -5.0 dorsal-ventral. Mice were treated 4 days’ post-
surgery with 0.5 mg/kg/day of the analgesic carprofen and allowed 6 days’ recovery prior 
to beginning training. 
ICSS Rate Frequency Procedure 
Mice were trained to respond on an FR1 at 141 Hz frequency at 100 uA. If 
responding did not equal or exceed 30 stimulation deliveries per minute the amperage was 
increase 25% and tested again. Following stable responding at ≥ 30 responses/min, mice 
were transitioned to a repeated 10-minute fixed ratio 1 with a 10-minute timeout at the set 
amperage from the FR1 and at 158 Hz. Following reliable responding during the active 
component (ratio > 8) mice were transitioned to a four component rate-frequency 
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procedure. Rate-frequency sessions were approximately 80 min, divided into four 10-min 
response components separated by time outs. The use of timeouts allowed for adequate 
time for treatment conditions to be applied between control and subsequent drug treatment 
curves within a single test session. Each response component consisted of ten 1-min trials 
beginning at a stimulation frequency of 158 Hz and descending by 0.05 log units in each 
subsequent trial. After the first response component and following a timeout, vehicle or air 
was administered five minutes prior to running two control response components which 
served as the baseline. After an additional timeout following the end of the 3rd component, 
treatment conditions were administered five minutes before the start of the 4th component. 
Toluene vapor concentrations of 1000, 3300 and 5600 parts-per-million (PPM) 
were examined. Test sessions with injected drugs were identical to toluene test sessions 
except that following the baseline response components, the mice were administered a S.C. 
injection of drug. D-methamphetamine was injected 5 min prior to the 4th component at 
doses of 0.3, 1, and 3 mg/kg. Ro15-4513 was tested at doses of 0.3, 1, and 10 mg/kg. 
Flumazenil was tested at doses of 1, 3, and 10 mg/kg. Flumazenil and Ro15-4513 were 
administered 6 min prior to the 4th component, a time interval chosen based upon previous 
pharmacokinetic studies in male C57 mice (Kida et al, 2003; Potier et al, 1988).  
Antagonism of Drug-facilitated ICSS 
 A single concentration of toluene vapor (3300 PPM) and dose of d-
methamphetamine (3 mg/kg), which produced roughly equivalent facilitation of ICSS, 
were utilized. Antagonism tests employed the same procedure previously described, with 
the exception that Ro15-4513 and flumazenil were administered 1 min prior to d-
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methamphetamine, diazepam or toluene treatment. In all cases Ro15-4513 and flumazenil 
were tested alone prior to being combined with toluene, d-methamphetamine or diazepam.  
Data Analysis 
 Data from the first 10-min response component were discarded as they have been 
shown to exhibit greater variability than data from subsequent components (Carlezon and 
Chartoff, 2007). Stimulations earned during each 1-min trial of the 2nd and 3rd air/vehicle 
exposure control components were averaged and used as the baseline for comparison with 
the 4th treatment component. For each mouse, data from each trial were expressed as a 
percentage of earned stimulations in the 1-min trial with the greatest number of earned 
responses, regardless of frequency, in the average baseline component. These values are 
reported as a percentage of the maximum control responses (%MCR). Data from the 
baseline and treatment component were compared individually for each drug dose or 
inhalant concentration by 2-way within subject repeated measures analysis of variance 
(ANOVA). To allow for comparisons between treatment conditions, for each experimental 
group (i.e. vehicle baseline control vs. vehicle + methamphetamine vs. Ro15-4513 + 
methamphetamine) respective control curves were compared to determine if they were 
significantly different from each other by two-way repeated measures ANOVA. As no 
control curves within a given study were significantly different the repeated control curves 
were averaged to a single baseline curve for comparison across experimental treatment 
conditions and analyzed by 2-way repeated measures ANOVA. Significant ANOVA 
effects were followed by Holm-Sidak multiple comparisons test to determine significant 
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differences at individual frequencies between the baseline and treatment conditions (Aickin 
and Gensler, 1996; Jason C. Hsu, 1996; Stanton A. Glantz, 2006). 
Microdialysis 
Surgical Procedure 
 Mice were pretreated with morphine (0.2 mg/kg) and implanted under isoflurane 
anesthesia with a 5 mm guide cannula (CXG-6, Eicom, San Diego, CA) just above the 
nucleus accumbens at 1.34 mm anterior-posterior, 1 mm medial-lateral, and -4.0 mm 
dorsal-ventral. Mice were treated for 3 days’ post-surgery with 0.5 mg/kg/day of the 
analgesic carprofen and allowed 6 days of surgical recovery.  
Microdialysis Test Procedure 
 Mice were fitted in an elastic swivel jacket/tether assembly connected to a 
suspended fluid swivel. A microdialysis probe with a 1 mm regenerated cellulose 
membrane (CX-I-6-01, Eicom) was inserted through the guide cannula with the membrane 
extending into the NAc. The mice were then returned to the microdialysis chamber. 
Artificial cerebrospinal fluid (ACF) was perfused through the probe at a rate of 1.2 
uL/min. Prior to beginning sample collection, probes equilibrated for at least two hours or 
until stable dopamine dialysate levels were achieved. Samples were collected every 7 min 
for up to 3.5 hours and protected from degradation by the addition of 2.5 uL 0.01M HCl. 
Dopamine concentrations were considered stable after three consecutive samples that 
varied by no more than 0.05 pg or 20% of the running mean. Sampling delay for the 
analyte traveling between the probe membrane tip and sample collection output was 
calculated to be roughly 8 minutes at a flow rate of 1.2 uL/min. After establishing a stable 
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baseline, saline was administered to examine the effects of injection on dopamine levels. 
After 5 additional samples, 45% HP-BCD vehicle or 1 mg/kg Ro15-4513 was administered 
1 min prior to a dose of 3 mg/kg d-methamphetamine or saline. An additional comparison 
group of 1 mg/kg Ro15-4513 + saline was used to determine the effects of Ro15-4513 
alone on dopamine levels. Samples were then collected for an additional 2 hrs. Each 
group’s pretreatment baselines were averaged for each respective group and then directly 
compared to each post injection time-point using multiple comparisons to determine 
significance. To determine significance between independent treatment groups, a 2-way 
mixed measures ANOVA was performed using Fisher’s LSD post-hoc tests to determine 
significance. Measurements are reported without subtracting the lag time between probe 
membrane tip and sample collector. 
HPLC analysis 
 Dialysate samples were analyzed using HPLC-EC (HTEC-500, Eicom) with a C18-
column (PP-ODS II, Eicom), graphite working electrode, and an Ag vs. AgCl reference 
electrode with an applied potential of +450 mV. Dopamine retention time and 
concentration were determined by comparison to a standard curve (0.01-100 pg/5 µL) 
established prior to analysis of each subject’s experimental samples. The lower limits of 
quantification were set at 0.1 pg. 
Data Analysis 
 HPLC data were analyzed by eDAQ PowerChrom software (eDAQ, Colorado 
Springs, CO). The mean dopamine concentration of the last set of consecutive stable 
samples before injections were defined as the baseline for each subject. Subsequent data 
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were then expressed as a percentage of this value. Data were analyzed by a 2-way 
(treatment x time) mixed ANOVA. Significant (p < 0.05) main effects and interactions 
were examined by Fisher’s LSD multiple comparisons post-hoc tests. 19 missing data 
points out of 432 total points were substituted using individual group mean data. Missing 
data was roughly equally distributed between vehicle + d-methamphetamine, Ro15-4513 + 
saline, and Ro15-4513+ d-methamphetamine groups. 
Histology 
 Microdialysis mice were euthanized with Euthasol (pentobarbital/phenotoin), their 
brains removed and grossly dissected to isolate the area containing the microdialysis guide 
cannula and probe tract. This tissue block was then immersed in 4% formalin for at least 
10 days. The block was then rinsed, placed in phosphate buffered saline and later sectioned 
using a Leica VT1000S vibratome (Buffalo Grove, IL). Sections were transferred to slides 
and stained with 0.1% cresyl-violet. Probe tract locations were identified using a 
stereotaxic mouse brain atlas (Paxinos and Franklin, 2001). 
Results 
Effects of abused drugs on ICSS 
Five minutes of exposure to toluene vapor facilitated ICSS over air control (Figure 
12a). The ANOVA found a significant treatment x frequency interaction [F (27, 162) = 
2.518, p = 0.0002]. Concentrations of 1000, 3300 and 5600 PPM toluene significantly 
increased %MCR over baseline at 1, 8 and 3 stimulation frequencies, respectively. D-
methamphetamine significantly facilitated ICSS over vehicle control (Figure 12b) 
producing a significant treatment x frequency interaction [F (27, 189) = 2.664, p < 0.0001]. 
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Doses of 0.3, 1 and 3 mg/kg d-methamphetamine significantly increased %MCR over 
baseline at 1, 8 and 8 stimulation frequencies, respectively. 
Effects of Flumazenil and Ro15-4513 administered alone on ICSS 
 Flumazenil when administered alone did not alter ICSS compared to vehicle 
(Figure 12c). There was neither a significant main effect of flumazenil treatment [F (3, 18) 
= 1.810, p = 0.1815] nor treatment x frequency interaction [F (27, 162) = 1.252, p = 
0.1968]. Ro15-4515 when administered alone significantly reduced responding for ICSS 
(Figure 1d) resulting in a main effect of Ro15-4513 treatment [F (3, 21) = 5.171, p = 
0.0078]. The 0.3 and 1 mg/kg doses of Ro15-4513 failed to alter ICSS relative to vehicle, 
whereas the 10 mg/kg dose significantly depressed %MCR relative to control at 3 
stimulation frequencies.  
Effects of flumazenil on drug-facilitated ICSS 
Pretreatment with 1 or 3 mg/kg flumazenil failed to block ICSS facilitated by 3300 
PPM toluene (Figure 2a). The ANOVA indicated a significant treatment x frequency 
interaction [F (27, 162) = 2.040, p = 0.0035] with vehicle + 3300 PPM toluene facilitating 
ICSS at 8 frequencies compared to control. The 1 and 3 mg/kg flumazenil + 3300 PPM 
toluene conditions significantly increased %MCR over control at 7 and 6 frequencies, 
respectively. Further %MCR in the 1 and 3 mg/kg flumazenil + 3300 PPM toluene 
conditions was not significantly lower than the vehicle + 3300 PPM toluene condition at 
any frequency. 
Pretreatment with 3 mg/kg flumazenil also failed to block ICSS facilitation 
produced by 3 mg/kg d-methamphetamine (Fig 13b). The ANOVA indicated a significant 
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main effect of treatment [F (2, 12) = 7.949, p = 0.0063] but no treatment x frequency 
interaction [F (18, 108) = 1.620, p = 0.0675]. Vehicle + 3 mg/kg d-methamphetamine 
significantly elevated responding at 6 frequencies over baseline control. The 3 mg/kg 
flumazenil + 3 mg/kg d-methamphetamine condition did not significantly suppress %MCR 
at any frequencies compared to the vehicle + 3 mg/kg d-methamphetamine condition 
resulting in the 3 mg/kg flumazenil + 3 mg/kg d-methamphetamine condition being 
significantly elevated over baseline control at 6 frequencies. 
Pretreatment with 3 mg/kg flumazenil completely blocked facilitation of ICSS 
produced by 3 mg/kg diazepam (Figure 13c). The ANOVA found a significant treatment x 
frequency interaction [F (18, 108) = 3.238, p < 0.0001]. The vehicle + 3 mg/kg diazepam 
condition was significantly elevated over baseline control at 3 frequencies. The 3 mg/kg 
flumazenil + 3 mg/kg diazepam treatment condition was significantly suppressed 
compared to the vehicle + 3mg/kg diazepam condition at 4 frequencies resulting in it not 
being significantly different from the baseline control at any frequency. 
Effects of Ro15-4513 on drug facilitated ICSS 
Pretreatment with 0.3 Ro15-4513 attenuated and 1 mg/kg Ro15-4513 completely 
blocked facilitation of ICSS produced by 3300 PPM toluene (Figure 13d). The ANOVA 
indicated a significant treatment x frequency interaction [F (27, 189) = 2.125, p = 0.0018]. 
The vehicle + 3300 PPM toluene condition was significantly elevated over baseline at 8 
frequencies. The 0.3 mg/kg Ro15-4513 + 3300 PPM toluene condition significantly 
suppressed %MCR at 5 frequencies when compared to the vehicle + 3300 PPM toluene 
condition resulting in it only being significantly different from baseline control at two 
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frequencies (Figure 13d). Responding in the 1 mg/kg Ro15-4513 + 3300 PPM condition 
was significantly suppressed at 6 frequencies compared to the vehicle + 3300 PPM toluene 
condition resulting in it not being significantly different from baseline at any frequency. 
Pretreatment with 0.3 and 1 mg/kg Ro15-4513 completely blocked facilitation of 
ICSS produced by 3 mg/kg d-methamphetamine (Figure 13e). The ANOVA found a 
significant main effect of treatment [F (3, 18) = 8.296, p = 0.0011] but no treatment x 
frequency interaction [F (27, 162) = 1.396, p = 0.1066]. The vehicle + 3 mg/kg d-
methamphetamine condition was significantly elevated over the baseline control at 4 
frequencies. Responding in the 0.3 mg/kg Ro15-4513 + 3 mg/kg d-methamphetamine 
condition was significantly suppressed at 4 frequencies compared to the vehicle + 3 mg/kg 
d-methamphetamine condition resulting in it not being significantly different from the 
baseline control condition at any frequency (Figure 13e). Responding in the 1 mg/kg 
Ro15-4513 + 3 mg/kg d-methamphetamine condition was significantly suppressed at 4 
frequencies compared to the vehicle + 3 mg/kg d-methamphetamine condition resulting in 
it not being significantly different from the baseline control condition at any frequency 
(Figure 13e).  
Pretreatment with 0.3 mg/kg Ro15-4513 also completely blocked facilitation of 
ICSS produced by 3 mg/kg diazepam (Figure 13f). The ANOVA found a significant 
treatment x frequency interaction [F (18, 108) = 1.767, p = 0.0388]. Vehicle + 3 mg/kg 
diazepam condition significantly facilitated responding at 2 frequencies compared to the 
baseline control (Figure 13f) whereas the 0.3 mg/kg Ro15-4513 + 3 mg/kg diazepam 
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treatment condition was not significantly different from the baseline control at any 
frequency. 
Maximum rates of responding across experimental conditions 
Maximum rates of responding in each test condition which were used to compute 
%MCR are reported in table 3. For each experimental condition, the maximum rate of 
responding in the baseline condition was not different from the treatment condition with 
the exception of 10 mg/kg Ro15-4513 alone and 1 mg/kg Ro15-4513 + 3 mg/kg d-
methamphetamine which were both significantly lower than baseline. 
NAc microdialysis 
 Mean baseline dopamine levels (±SEM) across all subjects prior to drug treatment 
was 1.29 ± 0.50 pg/5uL. Administration of vehicle 1-min prior to injection of 3 mg/kg d-
methamphetamine resulted in extracellular dopamine levels peaking at 903% of baseline 
21 min after d-methamphetamine injection (Figure 14). Administration of 1 mg/kg of 
Ro15-4513 1-min prior to d-methamphetamine attenuated maximal extracellular dopamine 
levels in the NAc which peaked at 434% of baseline. A mixed 2-way ANOVA 
demonstrated a treatment x time interaction [F (52, 338) = 4.978, p < 0.0001]. Post hoc 
analysis indicated that dopamine levels in the dialysate samples from 14-70 min post-
injection were significantly lower in the 1 mg/kg Ro15-4513 + 3 mg/kg d-
methamphetamine treatment group compared to the vehicle + 3 mg/kg d-
methamphetamine group. The vehicle + 3 mg/kg d-methamphetamine and 1 mg/kg Ro15-
4513 + 3 mg/kg d-methamphetamine conditions were significantly elevated over the mean 
pretreatment baseline at 14-77 and 14-91 time points post injection, respectively. 
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Dopamine in the 1 mg/kg Ro15-4513 + saline group was slightly elevated and was 
significantly greater at the 7-28, 42 and 56 min time points compared to pretreatment 
baseline. Two out of 18 subjects were excluded from the study due to inaccurate probe 
placement from the intended accumbens target. Approximate probe locations are plotted on 
a coronal histological brain atlas from Paxinos and Franklin and a representative 
micrograph are shown in figure 15 (Paxinos and Franklin, 2001). 
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Table 3 
Drug Dose Baseline±SEM Treatment±SEM 
Toluene (n=7) 1000 51.0±3.4 51.7±4.1 
  3300 51.5±4.1 52.0±4.0 
  5600 48.5±3.3 47.9±4.7 
Meth (n=8) 0.3 50.5±1.7 50.4±1.4 
  1 49.3±1.4 50.9±1.6 
  3 50.6±2.0 48.5±2.4 
Ro15-4513 (n=8) 0.3 51.8±3.7 47.3±4.0 
  1 54.1±3.8 49.3±4.9 
  10 52.1±3.5 42.3±4.4* 
Flumazenil (n=7) 1 43.1±2.0 48.3±2.9 
 
3 51.5±2.9 52.4±2.9 
10 47.2±3.5 51.4±4.5 
Ro15-4513 + 3300 PPM Toluene (n=7) 0.3 48.8±4.0 44.6±4.4 
  1 52.9±4.4 45.6±6.5 
Ro15-4513 + 3 mg/kg d-methamphetamine (n=7) 0.3 50.7±4.4 43.0±4.6 
  1 53.6±4.6 43.3±4.2* 
Ro15-4513 + Diazepam (n=7) 0.3 53.4±1.8 53.7±2.2 
Flumazenil + 3300 PPM Toluene (n=7) 1 43.9±2.3 49.3±3.3 
  3 47.6±3.3 47.1±3.4 
Flumazenil + 3 mg/kg d-methamphetamine (n=7) 3 49.6±2.1 52.4±1.9 
Flumazenil + 3 mg/kg Diazepam (n=7) 3 54.2±2.0 53.0±1.7 
Mean maximum response rates for each experimental condition. Differences in maximum response 
rates between baseline and treatment conditions were compared with a two-way mixed measures 
ANOVA with Holm Sidak's multiple comparisons test. * Indicates significant difference. 
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Figure 11 
 
Figure 11 Toluene concentration in the chamber as a function of time for 1000 to 5600 
ppm. Green area represents when the ICSS test session begins. 
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Figure 12 
 
Figure 12 Mean (±SEM) percent maximal control ICSS response rate (% MCR) following 
a 5 min (a) exposure to 1000-5600 PPM toluene vapor (b) pretreatment with 0.3-3 mg/kg 
d-methamphetamine (c) Pretreatment with 1-10mg/kg flumazenil (d) pretreatment with 
0.3-10 mg/kg Ro15-4513. Filled symbols denote significant differences compared to 
control (p < 0.05). 
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Figure 13 
 
Figure 13 Mean (±SEM) percent maximal control ICSS response rate (% MCR) following 
a pretreatment with vehicle, flumazenil or Ro15-4513 prior to 5-minute exposure to 3300 
PPM toluene vapor or to injection of 3 mg/kg d-methamphetamine or 3 mg/kg diazepam. 
(a) 3300 PPM toluene + vehicle, 1 or 3 mg/kg flumazenil. (b) 3300 PPM toluene + vehicle, 
0.3 or 1 mg/kg Ro15-4513 (c) 3 mg/kg d-methamphetamine + vehicle or 3 mg/kg 
flumazenil (d) 3 mg/kg d-methamphetamine + vehicle, 0.3 or 1 mg/kg Ro15-4513 (e) 3 
mg/kg diazepam + vehicle or 3 mg/kg flumazenil (f) 3 mg/kg diazepam + vehicle or 0.3 
mg/kg Ro15-4513. Filled symbols denote significant difference vs. control. * denote 
significant difference for labeled point vs pretreatment with 1 mg/kg flumazenil or 0.3 
mg/kg Ro15-4513, # significant difference for labeled point vs pretreatment with 3 mg/kg 
flumazenil or 1 mg/kg Ro15-4513. 
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Figure 14 
 
Figure 14: Mean baseline (±SEM) percent maximal dopamine levels as a percentage of 
control baseline for each respective group: Ro15-4513 + vehicle, vehicle + d-
methamphetamine, and Ro15-4513 + d-methamphetamine. Points prior to first downward 
arrow (Saline) indicate equilibration baseline dopamine levels. Second downward arrow 
(TX Inj.) indicates injection time of vehicle + 3 mg/kg d-methamphetamine (open circles), 
1 mg/kg Ro15-4513 + 3 mg/kg d-methamphetamine (grey squares), or 1 mg/kg Ro15-4513 
+ vehicle (grey triangle). Filled symbols denote significant difference compared to each 
treatment groups respective pretreatment mean (±SEM) dopamine baseline (p < 0.05). * 
denotes significant differences between vehicle + d-methamphetamine, 1 mg/kg Ro15-
4513 + 3 mg/kg d-methamphetamine (p < 0.05). 
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Figure 15 
 
Figure 15: Serial coronal sections along anterior-posterior plane from 0.86 to 1.42 mm 
relative to bregma and representative photomicrograph. Black lines indicate 1mm long 
microdialysis probe membrane tracts. Shaded region indicates approximate location and 
size of nucleus accumbens (Paxinos and Franklin, 2001). 
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Discussion Aim 2 
As expected based on prior studies, methamphetamine, toluene and diazepam all 
significantly facilitated ICSS responding (Bauer et al, 2013; Chan et al, 2012, 2015; 
Robinson et al, 2012; Tracy et al, 2014). Methamphetamine and toluene vapor produced 
comparably robust ICSS facilitation whereas the effect of diazepam on ICSS was modest 
relative to previous studies (Straub et al, 2010; Tracy et al, 2014). In the present study it 
was noted that increasing the toluene exposure concentration and shortening the pre-
exposure duration prior to ICSS testing resulted in a much greater facilitation of ICSS than 
that reported following a longer exposure to a lower toluene concentration (Tracy et al, 
2014). Although I did not explore this interaction systematically this finding parallels 
similar results with ethanol which also noted the greatest degree of ICSS facilitation was 
found immediately after alcohol administration (Fish et al, 2010). A shorter duration of 
exposure at higher toluene concentrations resulting in increased ICSS facilitation may be a 
result of conducting ICSS testing while drug levels are rapidly rising in the CNS. This 
interpretation is consistent with the observation in humans that the euphoric/hedonic 
effects of amphetamine and ethanol are most prominent when the drug plasma levels are 
on the ascending portion of the pharmacokinetic curve (Brauer et al, 1996; Lukas et al, 
1986a, 1986b).  
It was my goal to test the hypothesis that negative allosteric modulation of GABAA 
receptors via the benzodiazepine-site, rather than simply a blockade of the benzodiazepine-
site, would attenuate the reward-related effects of the inhalant toluene as it has been 
demonstrated and shown to produce substantial neuropharmacological effects at GABAA 
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receptors (Beckstead et al, 2000; MacIver, 2009). It was therefore important to 
differentiate the negative allosteric effects of Ro15-4513 from those produced by a BDZ-
site antagonist, which itself in limited cases has been shown to reduce some of the 
behavioral effects of some volatile anesthetics (Dias Cicarelli et al, 2016; Liang et al, 
2014). When the BDZ-site antagonist flumazenil was pre-administered before each drug, 
the ICSS facilitating effects of the BDZ site positive GABAA allosteric modulator 
diazepam were completely blocked by flumazenil. However, a dose of flumazenil 
sufficient to block a high efficacy benzodiazepine-site agonist had no effect on ICSS 
facilitation produced by either the monoamine releaser methamphetamine or the inhalant 
toluene. These data are consistent with flumazenil’s clinical profile as a BDZ antagonist 
(Votey et al, 1991) and supports previous literature demonstrating that neither toluene nor 
methamphetamine interact directly with the BDZ binding site of GABAA receptors (Páez-
Martínez et al, 2008). However, given toluene’s interaction with GABAA receptors it 
remains plausible that other behaviors produced through toluene’s positive allosteric 
modulation of GABAA receptors could be affected by flumazenil binding to the BDZ site 
such that the behavior could be altered.  
With respect to preadministration of Ro15-4513, it was able to completely block 
methamphetamine, toluene and diazepam-facilitated ICSS. While toluene has positive 
GABAA modulatory effects (Beckley and Woodward, 2013; Beckstead et al, 2000; Shelton 
and Nicholson, 2013; Williams et al, 2005), d-methamphetamine does not (Hondebrink et 
al, 2011). Therefore, the hypothesis that toluene’s reinforcement enhancing effects would 
be sensitive to Ro15-4513 negative allosteric GABAA modulation via the BDZ site is not 
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supported as Ro15-4513 blocked reward-like effects independently of the drugs 
pharmacological mechanism of action. Most surprisingly, the effect of Ro15-4513 on d-
methamphetamine facilitation trended towards being even more suppressed than toluene. 
The observation thus leads to supporting the possibility that negative allosteric modulation 
of GABAA receptors can strongly affect the reward-related effects of drugs of abuse in 
general, regardless of their specific pharmacological mechanism of action.  
It is important to note that Ro15-4513 has been previously shown to produce 
pronounced effects on operant behavior. For example, Ro15-4513 decreases operant 
behavior on a fixed ratio:15 and fixed interval:15 schedule of reinforcement in ICSS in rats 
(Schaefer and Michael, 1989). In self-administration studies in monkeys, an intramuscular 
injection at similar dosages as those used in this study produces generalized decreases in 
operant responding for both alcohol and a sweetened drink reinforcer (Shelton and Grant, 
2001). It is therefore possible that any suppression of ICSS produced by Ro15-4513 may 
have been the result of a non-selective attenuation of operant performance. To address this 
concern, I assessed the effects of both Ro15-4513 and flumazenil alone on ICSS 
responding. In the subsequent interaction study, I only tested the 0.3 and 1 mg/kg doses of 
Ro15-4513 and the 3 mg/kg dose of flumazenil which were all well below doses which 
produced measurable effects on ICSS. I therefore am relatively confident that the effects 
observed when flumazenil or Ro15-4513 were pre-administered before drug treatment 
were not a result of non-selective rate-altering effects. However, it is possible that a higher 
dose of flumazenil may have been able to produce a measurable effect in ICSS. Although 
at higher doses flumazenil may produce quantifiable effects as a weak negative modulator 
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at select subtypes of the GABAA receptor (File et al, 1986; De Vry and Slangen, 1985) or 
even produce weak positive modulatory effects at α1-2-containing GABAA receptors (Smith 
et al, 2001), the latter of which are believed to be involved in the reinforcing and 
reinforcement enhancing effects of benzodiazepines (Engin et al, 2014; Rudolph and 
Knoflach, 2011; Tan et al, 2010).  
A critical constituent in maintaining a subject’s responding in intracranial self-
stimulation is the indirect end stage component of mesolimbic dopamine release in the 
nucleus accumbens resulting from the direct phasic activation of neuronal substrates in the 
medial forebrain bundle. Therefore, it was plausible that Ro15-4513 would have little 
effect on mesolimbic dopamine release in the nucleus accumbens resulting from ICSS. 
However, it may substantially inhibit the ability of compounds to enhance mesolimbic 
dopamine release. To test whether Ro15-4513 was having a preferential effect on 
mesolimbic dopamine enhancement, I extended my behavioral results to a direct measure 
of mesolimbic dopaminergic activity utilizing a microdialysis procedure.  
I therefore examined whether Ro15-4513 would attenuate d-methamphetamine 
stimulated dopamine release in the NAc. The choice of only examining d-
methamphetamine was a pragmatic one, as amphetamine type stimulants are well 
established to produce much more robust dopamine release than either toluene or 
diazepam. It had been previously established that 3 mg/kg d-methamphetamine provided a 
sufficient experimental dynamic to detect changes in dopamine levels across multiple 
treatment conditions (Apawu et al, 2015; Invernizzi et al, 1991; Riegel et al, 2007). To 
allow direct comparison with the ICSS data, I utilized the same dose combination of 1 
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mg/kg Ro15-4513 with 3 mg/kg d-methamphetamine that was examined in the ICSS 
procedure and found to produce robust suppression of facilitation without producing a 
generalized suppression of ICSS responding when administered alone. Administration of 1 
mg/kg Ro15-4513 with 3 mg/kg d-methamphetamine produced a ~58% reduction in peak 
dopamine release compared to that produced by d-methamphetamine alone. In contrast, 
administration of 1 mg/kg Ro15-4513 alone resulted in only a small increase in baseline 
dopamine levels, the magnitude of which was quite small relative to baseline. Time course 
differences between testing in ICSS and the observed peak dopaminergic activity were 
minimally separated when accounting for the lag time between microdialysis probe tip, the 
length of the connecting tubing and the collection apparatus as well as previously observed 
temporal differences in ICSS performance and changes in mesolimbic dopamine (Leitl et 
al, 2013; Miller et al, 2015). Under the limited set of experimental conditions examined, 
these data substantiate that exogenously induced negative allosteric modulation of GABAA 
receptors can attenuate drug-stimulated dopamine release within the NAc.  
The critical modulatory role of GABAA receptors in the mesolimbic reward 
pathway is further supported by data showing that not only will systemically administered 
Ro15-4513 reduce drug reward-related behavior, but that Ro15-4513 microinjected into 
the posterior VTA of mice will reduce ethanol consumption without affecting non-drug 
reinforcers such as a 5% sucrose solution or water intake (Melón and Boehm, 2011). 
Additional evidence of the importance of GABAA receptors in modulating dopamine 
activity comes from non-pharmacological direct activation of VTA GABAergic neurons 
through optogenetics, which showed a profound effect on reducing the excitability on 
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downstream NAc dopamine release (van Zessen et al, 2012). A large population of these 
VTA GABAergic neurons provide local inhibitory GABA release onto dopaminergic 
neurons and in the presence of a negative allosteric modulator such as Ro15-4513 may 
significantly increase the interneuron’s release of GABA. An interesting observation 
within the VTA is the differential expression of α1 subunits in GABAA receptors located 
on VTA GABAergic neurons as compared to the presence of α3 subunits in GABAA 
receptors located on VTA dopaminergic projecting neurons (Tan et al, 2010). It has been 
reported that Ro15-4513 shows higher efficacy at α1-containing GABAA receptors for 
reducing chloride influx relative to α3-containing GABAA receptors (Smith et al, 2001). 
These data support a differential action of Ro15-4513 on VTA interneurons while having 
little to no effect on α3-containing GABAA receptors found on dopaminergic neurons 
themselves. 
These results, when combined with previous findings, suggest that Ro15-4513 may 
enhance the function of inhibitory VTA GABAergic interneurons, which may substantially 
contribute to a reduction of exogenously stimulated dopamine release in the NAc. The 
observed complete blockade of methamphetamine facilitated ICSS by Ro15-4513 may 
partially depend upon the observed decrease in NAc dopamine release. However, given I 
administered Ro15-4513 systemically there are a substantial number of additional 
GABAergic pathways that could contribute to the present behavioral and neurochemical 
results, especially given the microdialysis data showing that methamphetamine-stimulated 
dopamine release is attenuated but not entirely blocked by Ro15-4513. The actions of 
Ro15-4513 in the NAc may result from disinhibition of multiple subtypes of GABAergic 
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neurons that influence the activity of dopaminergic medium spiny neurons (Russo and 
Nestler, 2013) or through effects on GABAA receptors found in the NAc on neurons which 
provide GABAergic feedback to the dopaminergic neurons within the VTA (Xia et al, 
2011). Within the NAc, D1-containing medium spiny neurons project inhibitory feedback 
to the VTA which has been shown to preferentially release GABA on GABAergic 
neurons, some of which are known to provide inhibitory control of VTA dopaminergic 
projecting neurons. Repeated administration of drugs such as cocaine have been shown to 
strengthen the D1-containing medium spiny neuron ability to release GABA within the 
VTA, potentially enhancing the activity of dopaminergic neurons via disinhibition through 
inhibition of local VTA inhibitory GABAergic interneurons (Bocklisch et al, 2013). 
Other examples of GABAergic connection that can influence mesolimbic 
dopaminergic activity are GABAergic connections from the rostromedial tegmental 
nucleus (RMTg) that project to the VTA. Behavioral and neuroanatomical data suggest 
that activation of RMTg neurons inhibits the locomotor and reward-like functions found in 
midbrain dopaminergic cells and is important in mediating and encoding signals of 
aversive stimuli (Jhou et al, 2009). The RMTg has been described as functional ‘master 
braking system’ for the reward processing system and the presence of Ro15-4513 could 
serve to disinhibit RMTg inhibition of dopaminergic projecting neurons within the VTA 
(Barrot et al, 2012). Further, the RMTg receives excitatory glutamatergic input from the 
lateral habenula which itself has strong GABAergic innervation from the medial globus 
pallidus (Araki et al, 1984; Shabel et al, 2012). Ro15-4513 could therefore function to 
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enhance excitatory connections from the lateral habenula, which would further the drive 
the activation of the inhibitory RMTg on dopaminergic projecting neurons.  
Ultimately, given the diversity of GABAA receptors on neurons that feed into or are 
a part of the mesolimbic reward pathway, it is not possible to neuroanatomically isolate 
any one particular mechanism based on the present study. However, given the profound 
behavioral effects observed, determining whether the present results are the consequence 
of a specific regionally localized mechanism related to one GABAA receptor subtype or the 
summation of multiple GABAA receptor subtypes in several brain regions is an important 
future direction. 
In summary the current data set shows that GABAergic negative allosteric 
modulation attenuates drug facilitated ICSS in mice across three abused drugs with 
differing underlying mechanisms of action. Given the in vivo microdialysis data these 
behavioral results may be at least partially mediated by attenuation of drug-stimulated 
dopaminergic output within the mesolimbic reward pathway. However, Ro15-4513 is a 
fairly nonselective tool, producing negative allosteric action at all α1-3,5-containing GABAA 
receptors (BDZ-sensitive) which are ubiquitously expressed through mammalian brains, 
therefore additional work is needed to clarify the role of specific GABAA subunits in this 
effect. Future experiments involving more selective pharmacological tools may help 
identify the specific brain regions that contribute to depression and facilitation of ICSS 
produced by drugs of abuse. From a clinical standpoint, selective allosteric modulation of 
GABAA receptor subtypes may be a promising avenue for developing medications which 
reduce the abuse-related effects of drugs without the potential adverse side effects 
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associated with nonselective GABAA negative modulators (Pokk and Zharkovsky, 1997; 
Venault and Chapouthier, 2007). Lastly, these results in conjunction with the outcome of 
the clinical trial currently underway with the Ro15-4513 analog iomazenil for treatment of 
ethanol intoxication, may suggest implications for the use of GABAA negative modulators 
as therapeutics for attenuating the effects of other drugs of abuse (D’Souza, 2015). 
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Aim 3: Effects of Chronic Intermittent Toluene on ICSS and Nesting Behavior 
Materials and Methods 
Subjects 
 A total of 24 and 12 adult male C57BL/6J mice (Jackson Laboratory, Bar Harbor, 
Maine) were used for the ICSS and nesting procedures, respectively. Mice were 
individually housed under a 12h light/dark cycle and tested during the light phase of the 
cycle. Laboratory chow (Harlan, Madison, WI) and water were available ad libitum except 
during experimental sessions. All procedures were approved by the Institutional Animal 
Care and Use Committee of Virginia Commonwealth University and were in accordance 
with NIH guidelines (National Research Council, 2011).  
Compounds 
 Toluene was purchased from Fisher Scientific and stored in 500 mL Pyrex gas 
bubblers. 
Dynamic Vapor Exposure System and Testing Apparatus 
The inhalant exposure ICSS system consisted of four 20 liter acrylic cubicles each 
of which contained a two-lever operant conditioning chamber (Med-Associates, St. 
Albans, VT). A bipolar lead tether connection (Plastics One, Roanoke, VA) and mercury 
commutator (Mercotac 205L, Carlsbad CA) was suspended above the operant conditioning 
chamber by a counterbalanced arm. Toluene and TCE vapor were produced using a 
dynamic vapor generator composed of a filtered, pressure regulated air supply routed via 
tubing to two mass flow proportional valves controlled by a Matheson 8284 dynamic gas 
mixer (Matheson, Albuquerque, NM). The air output from one valve passed through a 
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fritted glass bubbler submerged below the liquid inhalant, generating an inhalant-laden air 
stream. The inhalant-laden air was mixed with metered fresh air from the second mass 
control valve permitting a broad range of highly reproducible inhalant concentrations to be 
generated. The blended vapor stream was routed through the upper rear wall of the operant 
conditioning chambers via Tygon tubing. The effluent mixture was tested from the front of 
the exposure chamber with a MiniRAE 2000 Volatile Organic Gas Detector (San Jose, 
CA). ICSS stimulation and operant schedule control was provided by commercially-
available components (Med-Associates, St. Albans, VT). A summary schematic of the 
operant conditioning chamber housed within the gas exposure system with the 
accompanying effluent mixture piping and delivery is shown in figure 1a.  
Chronic Dynamic Vapor Exposure System 
Six sealable polycarbonate food storage containers (325x265x200mm) were 
utilized to construct the chronic exposure system. A high pressure air source was 
connected to a regulator lowering the pressure to 5 PSI. The low pressure air was then split 
into two individual airline circuits each connected to an electrically-operated solenoid 
valve (Open-frame/8003G/H), the output of each solenoid valve was then connected to a 
Matheson 604 rotameter to control air and toluene vapor flow rates. Air from the toluene 
circuit rotameter was then routed through a gas stone submerged in a 500 mL gas wash 
flask filled with toluene, creating a toluene vapor-laden air stream. The toluene vapor-
laded air stream was then mixed with the independently regulated fresh air stream to 
produce a mixed stream at the appropriate toluene vapor exposure concentration. The 
mixed stream then flowed through a six channel divider to deliver toluene vapor to each of 
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the individual exposure chambers. Waste gas was expelled through a separate outflow 
circuit into a fume hood where it was evacuated from the building. 
Testing indicated that following two minutes of continuous toluene vapor delivery 
into the chamber, the toluene concentration approached the 3300 ppm target (Figure 16a). 
Figaro 2620 volatile organic gas sensors were utilized to monitor real time changes in 
toluene concentration within the environmental chambers. Near steady-state concentrations 
of toluene were maintained at 3300 ppm by an Arduino Mega 2560 R3 microcontroller 
which switched the toluene valve off and on according to a binary harmonic sine function 
shown in figure 16b. 
Gas Delivery Schedule 
 The gas delivery dosing schedule for the three experimental groups is shown in 
figure 17 (air control, chronic intermittent toluene and escalating chronic intermittent 
toluene). Subjects in the air control group received no toluene exposures but were 
otherwise treated identically to the toluene-exposed groups. Subjects in the chronic 
intermittent toluene (CIT) delivery and escalating chronic intermittent toluene (ECIT) 
delivery group were exposed to 3300 ppm toluene for 15 min every 72 hours beginning 
five minutes before the fourth component of the ICSS procedure. The escalating chronic 
intermittent group also received additional 15 min exposures to 3300 ppm toluene in their 
home cages. The daily number of additional exposures escalated every three days 
according to the following pattern: 1, 3, 6, 10 and 15 exposures (e.g. 1 exposure on days 1-
3, 3 exposures on days 4-6, etc.). The subjects in the chronic intermittent and escalating 
exposure group were tested in ICSS at least 6 hours after the most recent toluene exposure 
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in order to reduce the likelihood of residual blood toluene impacting the ICSS or nesting 
test results.  
IR/Vis Nesting and Monitoring Camera System 
 Twelve 2.1mm Wide Angle ELP Mjpeg Camera for Industrial Machine Vision 
(Ailipu Technology Co., Shenzhen, Guangdong, China) connected to three 4-Port 
independent USB Root Hub controller cards to allow for continuous video and image 
recording. The camera control script for the nesting procedure was developed in house on a 
Linux Mint 17.3 system using the Python 2.7 programming language and FFmpeg video 
and image library encoding software. These control programs have been made available 
for free download for academic or non-commercial purposes 
(https://github.com/metracy/METcamtimer). 
ICSS Surgical Procedure 
Mice were implanted under isoflurane and morphine (0.2 mg/kg s.c.) anesthesia 
with bipolar electrodes (Plastics One, Roanoke, VA) directed at the right medial forebrain 
bundle (Paxinos and Franklin, 2001). Coordinates relative to bregma were: -1.5 anterior-
posterior, 0.9 medial-lateral, and -4.9 dorsal-ventral. Mice were treated 4 days’ post-
surgery with 0.5 mg/kg/day of the analgesic carprofen and allowed 6 days’ recovery prior 
to beginning training. 
ICSS Rate Frequency Procedure 
Mice were trained to respond on a FR1 at 141 Hz frequency at 100 uA. If 
responding did not equal or exceed 30 stimulation deliveries per minute the amperage was 
increase 25% and training continued. If responding was still below criteria level, this 
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process was repeated. Any animal that failed to respond at criteria level at a stimulation 
amperage of 350 was removed from the study. Following stable responding at ≥ 30 
responses/min, mice were transitioned to a repeated 10-minute fixed ratio 1 with a 10-
minute timeout at the set amperage from the FR1 and a frequency of 158 Hz. Following 
reliable responding during the active component with a ratio greater than eight for the lever 
presses in the active 10-minute component over the inactive one, mice were transitioned to 
a four component rate-frequency procedure. Rate-frequency sessions were approximately 
65 min, divided into four 10-min response components separated by time outs. The use of 
timeouts between response components allowed for adequate time for vapor levels of 
toluene to reach near steady-state levels within the chamber to a single test session. Each 
response component consisted of ten 1-min trials beginning at a stimulation frequency of 
158 Hz and descending by 0.05 log units in each subsequent trial. On toluene test days, 
toluene exposure began five minutes before the start of the 4th ICSS component and 
continued for the duration of the 4th component (15 minutes of total toluene exposure per 
session). 
Nesting Procedure 
Pressed cotton nesting sheets (6 cm x 6 cm x 0.1 cm) were cut into six equal sized 
rectangular pieces and placed at each of the four corners and at adjacent edges at the 
midpoint of the polycarbonate home cage of the chamber, dividing the cage in six 
approximate equal rectangles. The time required for a subject to clear zones of the nesting 
material was measured over the course of 100 minutes. An overhead camera captured an 
image of the subject’s progress along a logarithmic time scale beginning at 34 seconds and 
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proceeding by 0.25 log units over the course of the 100 minute (6000 seconds) test session. 
A representative image of a mouse engaging in the nesting behavior is shown in figure 18. 
Due to a known effect of clean cages affecting behavioral performance (Bouchatta et al, 
2016; Negus et al, 2015), mice were only tested in their own home cage and cages were 
kept clean by gradual removal of old bedding and addition of new bedding to keep the 
integrity of olfactory cues. 
Data Analysis 
 In order to examine effects over time, the maximum number of earned stimulations 
from the second and third components during the first four days of the experiment were 
averaged for each subject to compute that subject’s baseline maximum earned responses 
(MER). Starting on day five, all earned stimulations for every component at each 
frequency were normalized by dividing it by each subject’s MER to allow for tracking 
changes in earned stimulations over time across the different experimental conditions. 
These percent values are reported as a percentage of the maximum control responses 
(%MCR). For each ICSS session, the baseline was taken as an average of the computed 
%MCR from the second and third components at each individual frequency. This allowed 
for the baseline of 10 values across the rate-frequency curve to be subsequently compared 
to the 10 values obtained following delivery of toluene exposure which began five minutes 
prior to the 4th ICSS component. 
For each individual day within the experiment, data from the baseline and 4th test 
component were compared individually within each group by 2-way within subject 
repeated measures analysis of variance (ANOVA) (Negus and Miller, 2014). GraphPad 
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version 7.0 for Windows (La Jolla, CA) was used for all analyses. For within session 
curves, significant (p < 0.05) main effects and interactions were subsequently examined by 
the two-stage step-up method of Benjamini, Krieger and Yekutieli to compare identical 
frequencies across the control and test components (Benjamini et al, 2006). This procedure 
for correcting for the multiple comparisons problem is more powerful than Bonferroni type 
corrections that provide for a strong correction for the overall the family-wise error rate 
(Glickman et al, 2014). This procedure gains power by assuming that either all 
comparisons that are being made either have a positive-dependence on each other (i.e. 
comparison of points along parallel curves) or that each comparison is independent of 
every other comparison. It does this by a two stage procedure that first controls for the 
false discovery rate of the hypotheses being tested by examining the overall P values of the 
comparisons being made in order to estimate the proportion of the null hypotheses that are 
actually true. The algorithm then uses the proportion of null hypotheses that are actually 
true to set the lower limit for when a P value is sufficiently low to be called a true 
discovery. 
In order to facilitate analyzing between group variables in an ICSS procedure, each 
baseline and treatment components had the area under the curve (AUC) calculated from 
the log transformed rate-frequency curve. Each AUC value was then turned into a 
percentage of the average of each groups first four pre-toluene or pre-air exposure days by 
dividing each day’s AUC by their group average AUC. All references to %pre-exposure 
baselines or AUC are referring to this data having being normalized in this manner.  
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These values were then examined in a two-way mixed measures ANOVA 
comparing differences in baseline brain stimulation across all three test groups. In addition, 
a linear regression model was fitted to the baseline AUC group data to determine 
relationships between a continuous predictor variable (repeated toluene exposures) and the 
area under the curve (the overall amount subjects respond for varying intensities of brain 
stimulation across a rate frequency entire curve). An advantage of using linear regression 
in addition to the ANOVA is that ANOVAs ignore the order of cumulative repeated 
exposures and treat each test exposure as a factor independent of any directional trend 
(Motulsky and Christopoulos, 2004). Significance was determined by comparing the y-
intercept (the baseline starting point) ± SEM and the slope (rate of change for each group) 
± SEM between regression lines and whether the 95% confidence intervals for the two 
regression lines overlapped across the modeled data sets.  
Chronic Intermittent Exposure Effects on Baseline and Drug Facilitated Brain Stimulation 
Reward 
To assess the effects of repeated toluene exposure on responding for brain-
stimulation following acute toluene exposure, ECIT subjects were assessed in ICSS after 
six hours of air exposure since their last 15-minute exposure to toluene. This period of air 
exposure was designed to reduce any residual toluene blood levels in the ECIT exposed 
group to trace levels. To examine whether CIT exposure would produce changes in its 
reinforcement enhancing effects of brain stimulation, toluene was assessed in ICSS every 
72 hours for the CIT and ECIT exposure groups following a baseline period of 5 days. 
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Area under the curve was computed by transforming the frequency to a log scale and 
summing the area under the baseline and 4th test component curves. 
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Results 
Effect of Repeated Exposures of Toluene on Acute Toluene-facilitated ICSS 
The results for the individual within-subject two-way repeated measures ANOVAs 
are shown in table 4. Each group’s daily baseline ICSS rate frequency curve was compared 
to their respective 4th component ICSS curve. For the control group, only air was 
administered across all 24 days during the 4th component. For the chronic intermittent 
toluene (CIT) and escalating chronic intermittent toluene (ECIT) exposure groups, on days 
5, 8, 11, 14, 17, 20 and day 24 a concentration of 3300 PPM toluene was administered 5 
minutes before the 4th component. For the CIT and ECIT groups that were exposed to 
toluene, at no point in the days in which they were only exposed to air did their within-
session baseline ICSS curve differ from their air treatment condition (4th component). A 
detailed summary of significant 2-way within-subject ANOVA data is shown in Table 4. 
In summary, for the chronic intermittent exposure group on days in which 3300 ppm 
toluene was administered prior to the 4th component, the number of significantly facilitated 
frequencies are as follows: test day 5 – 7 frequencies, test day 8 – 7 frequencies, test day 
11 – 7 frequencies, test day 14 – 10 frequencies, test day 17 – 7 frequencies, test day 20 – 7 
frequencies, test day 24 – 7 frequencies. For the escalating chronic intermittent exposure 
group on days in which 3300 ppm toluene was administered prior to the 4th component, the 
number of significantly facilitated frequencies are as follows: test day 5 – 6 frequencies, 
test day 8 – 5 frequencies, test day 11 through 17 – NS, test day 20 – 3 frequencies, test 
day 24 – NS frequencies. 
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Area under the Curve of Repeated Exposures of Toluene in ICSS 
The percentage of pre-exposure baselines for the CIT and the ECIT experimental 
conditions (toluene exposure) were compared to allow for a direct comparison of toluene’s 
facilitatory effect as a function of repeated cumulative exposures of toluene. A two-way 
between groups ANOVA was conducted on the two groups (Figure 19). There was a 
significant main effect of toluene exposure schedule on the area under the curve [F (1, 77) 
= 62.78 P < 0.0001], no effect of exposure day [F (6, 70) = 0.8834, P=0.5113], but a 
significant interaction [F (6, 70) = 2.432, P=0.0450]. For the ECIT group, the AUC on the 
3, 4, 5, 6 and 7th acute exposure tests on were significantly below the facilitation produced 
by the CIT group, suggesting tolerance to the acute reinforcing effects between group 
types. When the ECIT toluene tests were compared to their first toluene test, the 3, 4, 5 and 
6th tests were significantly depressed, indicating a tolerance compared to their first 
reinforcement enhancing. 
ICSS test day comparison of within-group baseline to its test condition 
When a linear regression model was applied to the air control group’s baseline and 
air treatment test days, the null hypothesis that one regression model would fit both data 
sets was tested and accepted [F (2, 68) = 0.109, p = 0.8969]. The model fit both data sets 
with an adjusted r2 of 0.8433 (figure 20a). The best fit value for the Y-intercept for both 
data sets was 95.02±6.563. The best fit value for the slope for the regression for both data 
sets was 0.7867±1.685. 
When a linear regression model was applied to the CIT group’s baseline and acute 
toluene exposure test days, the null hypothesis that one regression model would fit both 
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data sets was tested and rejected [F (2, 68) = 57.98, p < 0.0001]. The models fit each data 
sets with an adjusted r2 of 0.853 for the baseline and a r2 of 0.8607 (figure 20b). The best 
fit values for the Y-intercept for the baseline regression line was 111.1±10.77 and for the 
test baseline was 165.9±8.154. The best fit values for the slope for the baseline regression 
line was 0.3295±2.765 and for the test baseline was 2.872±2.094. 
When a linear regression model was applied to the ECIT group’s baseline and acute 
toluene exposure test days, the null hypothesis that one regression model would fit both 
data sets was tested and rejected [F (2, 68) = 6.935, p = 0.0018]. The models fit each data 
set with an adjusted r2 of 0.8544 for the baseline and an r2 of 0.8756 (figure 20c). The best 
fit values for the Y-intercept for the baseline regression line were 95.34±14.23 and for the 
test baseline was 152.8±15.03. The best fit values for the slope for the baseline regression 
line was -2.133±3.654 and for the test baseline was -9.596±3.86.  
 
Effects of Escalating Chronic Intermittent Toluene Exposure on ICSS Baseline Responding  
To compare how each group’s baseline changed across the experimental sessions, 
the three groups were compared with a two-way mixed groups ANOVA. There was a 
significant main effect of treatment condition [F (2, 300) = 11.95, P<0.0001] but no effect 
of exposure day [F (19, 300) = 0.306, P=0.9981] nor a significant interaction [F (38, 300) 
= 0.5017, P=0.9942].  
When a linear regression line was applied to the AUC of the baseline stimulations 
across the CIT and ECIT groups the null hypothesis that one regression line would fit both 
data sets was tested and rejected [F = 3.459 (2, 354), P = 0.0325]. The regression models 
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fit the data with an adjusted r2 of 0.841 and 0.84447 for CIT and ECIT groups respectively. 
The two lines with 95% confidence intervals are plotted in figure 21. The best fit values for 
the Y-intercept for the CIT regression line were 101.8±5.161 and for the ECIT regression 
line was 100.6.8±6.543. The best fit values for the slope for the CIT regression line was 
0.5285±0.4308 and for the ECIT was -1.125±0.5387. 
 
Rate-frequency curves at first exposure and 5th Exposure for Air, CIT and ECIT Groups 
A comparison of the rate-frequency curves across the three groups at the first test 
day (day 5) and the 5th test day (day 17) are shown in figure 22. A two-way within-subject 
ANOVA was performed on the %MCR for baseline and exposure test for each group on 
day 5 and 17. For the air control group on test day 5, the baseline curve did not 
significantly differ from the air exposure condition (Figure 22a). On day 17, again, the 
baseline curve did not significantly differ from the air exposure condition (Figure 22b).  
For the CIT group on day 5 (Figure 22c), there was a significant main effect [F (1, 
5) = 7.416, P = 0.0416)] but no significant drug x frequency interaction [F (9, 45) = 1.258, 
P=0.2860] with responding at 7 frequencies significantly increased over control. For the 
CIT group on day 17 (Figure 22d), there was a significant main effect [F (1, 5) = 21.96, 
P=0.0054] and a significant drug x frequency interaction [F (9, 45) = 3.763, P =0.0014] 
with responding at 7 frequencies significantly increased over control.  
For the ECIT group on day 5 (Figure 22e), there was a significant main effect [F 
(1, 5) = 31.8, P=0.0024] and a significant drug x frequency interaction [F (9, 45) = 2.836, 
P = 0.0099] with responding at 6 frequencies significantly increased over control. For the 
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ECIT group on day 17 (Figure 22f), there was no significant main effect [F (1, 5) = 
0.005352, P=0.9445] and no significant drug x frequency interaction [F (9, 45) = 1.616, 
P=0.1395] with responding at no frequencies different than control. 
 
Effects of Chronic Intermittent Toluene Exposure on Nesting Behavior 
The area under the curve for the air control and escalating chronic intermittent 
exposure condition were computed to allow for direct comparison of repeated toluene 
exposure on performance in the nesting procedure while in a drug free state. A two-way 
between groups ANOVA was conducted between the two groups (Figure 23). There was a 
significant main effect of exposure day on the area under the curve [F (19, 200) = 5.864, P 
<0.0001], no main effect of exposure day [F (1, 200) = 3.375, P=0.0677] but there was a 
significant interaction [F (19, 200) = 1.949, P=0.0126]. Post-hoc analysis revealed nesting 
performance on day 13 following 6 exposures/day, day 14 following 10 exposures/day, 
and day 15 following 10 exposures per day was significantly decreased for the chronic 
escalating group compared to air control. 
Acute Exposure of Toluene on Nesting Behavior 
 Acute exposure to 15 minutes of 3300 ppm toluene resulted in a significant right 
and downward shift in the nesting completion time curve (Figure 24). A two-way within-
subject repeated measures ANOVA was conducted on mice that were first exposed to air 
and subsequently to toluene. There was a significant main effect of time on zone [F (10, 
50) = 111.7, P<0.0001], a significant main effect of toluene exposure [F (1, 5) = 147.7, 
P<0.0001], and a significant interaction [F (10, 50) = 3.188, P=0.0031]. 
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Table 4 
Exposure Day Control CIT ECIT 
1 Air NS NS NS 
2 Air NS NS NS 
3 Air NS NS NS 
4 Air NS NS NS 
5 Air/Tol NS 7↑ 
ME: [F (1, 5) = 7.416 , P=0.0416] 
  
 
6↑ 
ME: [F (1, 5) = 31.8 , P=0.0024] 
INT: [F (9, 45) = 2.836 , P=0.0099] 
 
6 Air NS NS NS 
7 Air NS NS NS 
8 Air/Tol NS 7↑ 
ME: [F (1, 5) = 2.334 , P=0.0297] 
  
 
5↑ 
ME: [F (1, 5) = 21.56 , P=0.0056] 
INT: [F (9, 45) = 5.445 , P<0.0001] 
 
9 Air NS NS NS 
10 Air NS NS NS 
11 Air/Tol NS 7↑ 
ME: [F (1, 5) = 27.55 , P=0.0033] 
INT: [F (9, 45) = 3.804 , P<0.0012] 
 
  
NS 
12 Air NS NS NS 
13 Air NS NS NS 
14 Air/Tol NS 10↑ 
ME: [F (1, 5) = 45.16 , P=0.0011] 
INT: [F (9, 45) = 3.286 , P<0.0037] 
 
NS 
15 Air NS NS NS 
16 Air NS NS NS 
17 Air/Tol NS 7↑ 
ME: [F (1, 5) = 21.96 , P=0.0054] 
INT: [F (9, 45) = 3.763 , P<0.0014] 
 
NS 
18 Air NS NS NS 
19 Air NS NS NS 
20 Air/Tol NS 7↑ 
ME: [F (1, 5) = 12.43 , P=0.0168] 
INT: [F (9, 45) = 5.348 , P<0.0001] 
 
1↑2↓ 
INT: [F (9, 45) = 3.521 , P= 0.0023] 
 
21 Air NS NS NS 
22 Air NS NS NS 
23 Air NS NS NS 
24 Air/Tol NS 7↑ 
ME: [F (1, 5) = 28.21 , P=0.0032] 
INT: [F (9, 45) = 3.208 , P<0.0044] 
 
NS 
 
Table 4: Statistical difference in ICSS using within-session responding during the baseline 
component (Air) and testing component (Air/Tol) for control, chronic intermittent toluene 
(CIT), and Escalating Chronic Intermittent Control (ECIT). Red denotes toluene test days 
for CIT and ECIT. ME – Main Effect, INT – Interaction, NS represents not significant, # 
and the arrow ↓↑ represents number of statistically significant facilitated points on the 
curve and the direction of significance for the frequency in the testing component.   
122 
Figure 16a 
 
Figure 16a: Toluene concentration as measured with volatile organic compound sensors. 
The red line is the best fit non-linear regression line to an average (±SEM) of the sensor 
data collected within three of the polycarbonate chambers during toluene exposure. 
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Figure 16b 
 
Figure 16b: Blue line y1 represents oscillating function that varies with time that provides 
the necessary temporal separation for maintaining a relatively continuous concentration of 
toluene within the chamber. When the binary function shown by the black line y2 is 1, the 
toluene solenoid valve is set to on and air allowed to bubble through the 500 ml bubbler. 
When set to 0 the valve remains shut off. 
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Figure 17 
 
Figure 17: Order and schedule of the three ICSS and two nesting experimental groups. Red 
represents test days where Chronic Intermittent and Escalating Chronic Intermittent 
exposure groups were administered toluene five minutes before the start of the fourth 
component.  
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Figure 18 
 
Figure 18: Still frame from the video feed at the start of the nesting procedure. Six 
individually placed nestlets are placed at the six positions and throughout the course of the 
100 min session the mice will consolidate the nestlets into a corner. 
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Figure 19 
 
Figure 19: Comparison of acute toluene exposure on facilitation of ICSS relative to toluene 
pre-exposure baselines. Statistical significance between CIT and ECIT test day is denoted 
by filled black squares. * denotes statistical significance from ECIT’s first toluene test. 
Number of cumulative exposures prior to each test for each group are bound in the black 
boxes. 
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Figure 20 
 
Figure 20: ICSS test day data showing the area under the curve for baseline and test 
components that were performed on day 5, 8, 11, 14, 17, and 20. All data are shown as a 
percentage of their pre-exposure baselines from day 1-4 with regression lines drawn for the 
baseline in dashed blue and test component in dashed red a) Air control baseline data 
(white circle) with air test exposure data (blue square) b) Chronic intermittent baseline data 
(white circle) and acute 3300 ppm toluene exposure (red square). c) Escalating chronic 
intermittent baseline data (white circle) and acute 3300 ppm toluene exposure (red square).  
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Figure 21
 
Figure 21: Linear regression lines with 95% confidence intervals (shaded areas) for trend 
lines fitting the comparison of the %Pre-Toluene Exp. Baseline for the area under the 
curve for baseline stimulations earned within ICSS for the chronic intermittent toluene 
(CIT) exposure and the escalating chronic (ECIT) exposure groups. 
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Figure 22 
 
Figure 22: ICSS Rate-frequency data for test day 5 and test day 17 for air control, CIT and 
ECIT groups. Statistical significance between adjacent frequencies denoted by filled black 
symbol. a) Air control group baseline rate-frequency curves for baseline compared to air 
exposure on day 5. b) Air control group baseline rate-frequency curves for baseline 
compared to air exposure on day 17. c) CIT group baseline rate-frequency curves for 
baseline compared to 3300 ppm toluene exposure on day 5. d) CIT group baseline rate-
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frequency curves for baseline compared to 3300 ppm toluene exposure on day 17. e) ECIT 
group baseline rate-frequency curves for baseline compared to 3300 ppm toluene exposure 
on day 5. f) ECIT group baseline rate-frequency curves for baseline compared to 3300 ppm 
toluene exposure on day 17. 
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Figure 23 
 
Figure 23: Comparison of the nesting data using the area under the curve for each day to 
compare air control and repeated chronic escalating toluene (ECIT) exposure in the nesting 
procedure. Statistical significance is denoted by filled black squares. 
  
132 
Figure 24 
 
Figure 24: Number of zones cleared in the nesting assay during baseline and acute 
exposure from naïve mice. Statistical significance denoted by filled black symbols. 
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Discussion Aim 3 
Previous literature has demonstrated that across a broad range of drug classes and 
ICSS test conditions, that following repeated administration of drugs of abuse there is an 
emergence of anhedonic-like effects. These effects can be quantified in ICSS using 
multiple response parameters such as curve shifts or increases in threshold that account for 
changes in responding for direct electrical stimulation of the mesolimbic reward pathway 
(Holtz et al, 2015; Markou and Koob, 1991; Paterson et al, 2000; Schulteis et al, 1995; 
Stoker and Markou, 2011). Based upon the results in figure 21, the ECIT toluene group 
produced a significant negative slope downwards relative to repeated exposures to CIT. 
The negative slope indicates that as a function of escalating repeated toluene exposures the 
reinforcing efficacy of brain self-stimulation decreases. This result would be consistent 
with the hypothesis that escalating the number of toluene exposures produces a cumulative 
decrease in overall responding for brain stimulation while in a drug free state. Indicating 
that repeated toluene exposure decreases the functionality of the mesolimbic dopamine 
system. 
Interestingly, the decrease in the reinforcing efficacy of mesolimbic brain self-
stimulation in ICSS in part agrees with a recent striatal dopamine dynamics study in which 
it was demonstrated that a significant decrease in levels of electrically evoked dopamine 
release in the nucleus accumbens core and shell occurred 24 hours after repeated 2000 or 
4000 ppm toluene exposure for seven days (Apawu et al, 2015). However, it is difficult to 
draw conclusions comparing the results as the toluene concentrations, exposure times, 
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exposure schedules and withdrawal times were all different relative to the ones in this 
study.  
Across the air and CIT groups, the results from the within-session comparisons in 
table 4 combined with baseline data over time (Figure 20a-b) showed that the baselines for 
these two groups remained relatively stable while ECIT produced a negative trend in 
baseline stimulations over time (Figure 20c and Figure 21). The first major comparison 
was within-groups. The cumulative effect of toluene exposure in the ECIT group decreased 
the degree of facilitation resulting from acute toluene (Figure 20c) as well as the number of 
frequencies that were significantly facilitated (Table 4). When acute toluene was tested in 
the CIT group, the cumulative effect of previous toluene exposures every three days did 
not appear to affect toluene’s acute ability to facilitate ICSS (Figure 20b and Table 4).  
The ECIT group’s result is interesting in that the rate at which the groups baseline 
declined (negative slope Figure 20c) over repeated exposures was substantially less 
compared to the rate at which the ECIT’s acute toluene exposure declined to baseline 
levels. Contrary to most observed effects in ICSS involving escalating dosages of a drug, 
most studies have reported tolerance to their rate-decreasing effects. An example of this 
phenomenon is with morphine, in which escalating dosages unmask otherwise initially 
weak drug-induced ICSS facilitation (Altarifi and Negus, 2011). Interestingly the 
tolerance-like effect observed with acute toluene in the study has not been reported in the 
literature for other drugs of abuse. However, sensitization to toluene in other behaviors 
such as locomotion has been observed (Apawu et al, 2015; Bowen et al, 2010), though the 
chronic effects of repeated toluene exposure have not been explored in great detail in 
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ICSS. Therefore, it is entirely possible that use of different exposure concentrations, 
exposure durations, or utilizing an intermediate schedule between the observed 
diminishing toluene facilitation in the ECIT group and the relatively unchanging toluene 
facilitation observed in the CIT may produce more diverse behavioral results in ICSS. For 
example, the significant increase in magnitude of facilitation seen by increasing the 
concentration of toluene and shortening the duration of exposure in the acute toluene ICSS 
studies described in Aim 1 and 2 may have similar parallels within chronic exposure ICSS 
paradigms described in Aim 3. 
My third hypothesis was that following cessation from an escalating chronic 
intermittent toluene exposure schedule, responding for brain stimulation would be further 
suppressed. Presumably, following the last toluene exposure on day 20, any physiological 
compensatory changes induced to oppose the effects of repeated toluene exposure would 
not have returned to pre-exposure levels. Therefore, it was plausible that in the absence of 
toluene exposure the daily baselines measured in ICSS could further decrease, which 
would be indicative of a withdrawal syndrome. Twenty-four hours following the last 
exposure to escalating toluene exposures on day 21, the ECIT exposure group’s baseline 
remained at levels consistent with the previous four days. Subsequently there was no 
significant shift in ECIT’s baseline through day 24 indicating the absence of any 
spontaneous protracted withdrawal effects as compared to the acute withdrawal effects 
measured by the daily baselines on days 18, 19 and 20. Therefore at least under these set of 
conditions, the hypothesis that cessation of toluene from the escalating chronic intermittent 
exposure schedule would further suppress ICSS responding is rejected. 
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My fourth hypothesis was that repeated chronic intermittent exposure to toluene 
would produce gradual deficits in goal-directed behaviors other than ICSS as measured by 
the nesting procedure. The results showed that the ECIT group in the nesting procedure did 
significantly fall below the air control levels of completing the nesting procedure on three 
days. Figure 23 shows that after multiple trials for the air control group the baseline 
gradually shifted upwards, indicating a learned component in the procedure that enhances 
performance. The presence of a learned component complicates interpretation as repeated 
toluene exposure has been shown to produce adverse effects on learning and memory tasks 
(Dick et al, 2014) and this is why the nesting procedure was performed in a drug free state 
to minimize this direct effect as we demonstrated that acute exposure disrupts nesting 
behavior (Figure 24). Additionally, repeated escalating toluene exposure has been shown 
to alter glutamatergic and GABAergic in the hippocampus (Bale et al, 2005) which may 
impact or slow the rate of enhancing performance of nesting behavior. Therefore, it is 
entirely likely that multiple processes may be co-occurring for the escalating chronic 
intermittent group with manifestation of withdrawal effects at the same time as they 
continue to increase in performance as a result of repeated trials. By day 12 (figure 23), for 
the chronic intermittent group the separation between the two groups begins. Finally, by 
day 13-15 the groups have significantly separated as measured by the two-way repeated 
measures ANOVA post-hoc test. However, despite repeated chronic intermittent toluene 
from day 14 onwards the linear trend for the chronic intermittent exposure group is a 
constant climb through day 17 (first day no toluene exposure) until the data are not visually 
different from the air control group. Thus interpretation of nesting with all these possible 
137 
opponent processes co-occurring makes clear and simple interpretation difficult. In future 
studies however it would be highly advantageous to determine performance characteristics 
such that a ceiling effect could be reached to allow for a steady baseline for control and 
treatment groups prior to applying manipulations. Alternatively, if relatively stable 
performance enhancement rates can be established utilizing this rate of change as a metric 
to assess the influence of drugs or on it. 
In summary, the chronic ICSS experiment demonstrated a number of key points. 
One, that regardless of treatment condition, baseline ICSS stimulations in a drug-free state 
did not significantly change over the course of treatment in the air and CIT groups. In the 
ECIT group, the regression trended downwards across the escalating exposure days, which 
may be indicative of a mild withdrawal-associated physical dependence. These 
experiments demonstrated the utility of this procedure to be further explored with 
alternative schedules of inhalant exposure or other inhalants all together.  
Another remarkable feature that was captured on this initial first experimental run 
was the tolerance effect of toluene to facilitate ICSS by repeated escalating numbers of 
exposures. Given the wide availability of inhalants and the relatively rapid tolerance shown 
to its reward-like effects through escalating chronic intermittent use, these results may be 
directly relevant to helping understand substance abuse patterns in clinical populations, as 
inhalants are often reported to be one of the first types of substances abused among young 
individuals (Howard et al, 2011). 
As for the utility and future uses for the nesting procedure, there are interesting 
aspects to explore in how it could be used and modified to model clinical relevant features 
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of inhalant abuse. One example may be one of the relevant diagnostic criteria within the 
DSM 5 for inhalant substance use disorders, the functional impairment associated with 
normal everyday tasks (American Psychiatric Association, 2013). One of the important 
questions that could be further explored is what parameters could be used to improve the 
reliability of stable generation of detailed behavioral curves. One possibility would be 
doubling or tripling the dependent measure, zones cleared, by increasing the number of 
nestlets. However, given the labor difficulty and time consuming nature of analyzing 
image data from the nesting procedure, adoption of image recognition tools to automate 
the process may be necessary.  
Taken together, this exploratory aim searched for new ways in which procedures 
and technologies could be utilized to investigate the devastating effects of chronic inhalant 
abuse. These results extend the utility of intracranial self-stimulation procedures to 
investigate cumulative effects of repeated chronic inhalant exposure to measure acute 
withdrawal effects to investigate inhalants. Given the somewhat limited avenues available 
to study the full spectrum of inhalants abuse (Aim 1, Bespalov et al, 2003; Tracy et al, 
2014, 2015; Yavich et al, 1994), ICSS may prove to be a very useful tool to explore 
chronic exposure effects. 
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